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Abstract 
 
VIRGINIA ELAINE CARNAHAN: Characterizing the Pregnane X Receptor’s 
Interactions and Biophysical Properties 
(Under the direction of Dr. Matthew R. Redinbo.) 
 
Pregnane X Receptor is a ligand-activated transcription factor critical in 
protecting tissues from xenobiotics and endobiotics. PXR is shown to interact with GRIP-
1 and PGC-1α on DR-4 and XREM-CYP3A4 promoters. Experiments with full-length 
PXR have been limited by the inability to produce it. This study reports production of 
full-length PXR from Spodoptera frugiperda and use in peptide phage display 
experiments. PXR LBD was also mapped using peptide phage display. Sequencing 
results demonstrate a conserved motif consistent with class II nuclear receptor boxes but 
adding an additional residue, a polar residue in the -3 position. There is a novel 
intermolecular β-sheet mediating homodimerization in all PXR LBD structures. 
Mammalian two-hybrid studies demonstrated that a mutant of PXR that disrupts the 
homodimerization interface and eliminates basal transcriptional activity is unable to 
recruit SRC-1. Thermal denaturation studies of other PXR LBD mutants that affect basal 
transcriptional activity show changes in overall protein stability. 
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Abstract 
 
The Pregnane X Receptor (PXR; NR1I2; also termed PAR, SXR) is a member of 
the nuclear receptor family of ligand-regulated transcription factors.  Like many former 
orphan nuclear receptors, it contains both DNA and ligand binding domains, and binds to 
response elements in the regulatory regions of target genes as a heterodimer with RXRα.  
Unlike the vast majority of nuclear receptors, however, PXR responds to a wide variety 
of chemically-distinct xenobiotics and endobiotics, regulating the expression of genes 
central to both drug and bile acid metabolism.  We review the structural basis of PXR’s 
promiscuity in ligand binding, its recruitment of transcriptional coregulators, its potential 
formation of higher-order nuclear receptor complexes, and its control of target gene 
expression.  Structural flexibility appears to be central to the receptor’s ability to conform 
to ligands that differ in both size and shape.  We also discuss the clinical implications of 
PXR’s role in the drug-drug interactions, cancer, and cholestatic liver disease.  
 
 3
Introduction 
 
The pregnane X receptor (PXR; NR1I2; also PAR, SXR) is a member of the 
nuclear receptor superfamily that plays a central role in protecting tissues from 
potentially toxic exogenous and endogenous compounds (xenobiotics and endobiotics, 
respectively). Originally an orphan receptor, PXR was cloned based on sequence 
homology to other nuclear receptors (NRs) and prior to assignment of its cognate ligand 
or its biological function.  It was found first to respond to endogenous pregnanes, which 
gave rise to its name, but was subsequently shown to detect a wide variety of endobiotics 
and xenobiotics including many clinical drugs, with typical EC50’s in the high nanomolar 
or low micromolar range (Bertilsson, G., et al. 1998; Blumberg, B., et al. 1998; Kliewer, 
S.A., et al. 1998; Lehmann, J.M., et al. 1998). PXR has since been firmly adopted as a 
xenobiotic receptor that regulates the expression of numerous drug metabolism genes, an 
endobiotic sensor involved in regulating cholesterol homeostasis and bile acid 
metabolism genes, and as an important player in the development of specific forms of 
cancer.   
In this review, we examine numerous aspects of the structure and function of 
PXR.  We first cover the regulation of PXR, in terms of its activation by ligands, its 
interaction with transcriptional coregulators, the retinoid X Receptor (RXRα) and DNA, 
as well as documented single nucleotide polymorphisms (SNPs), subcellular trafficking 
and degradation.  Second, we examine what biological pathways are regulated by PXR, 
focusing on its well established roles in drug and cholesterol metabolism.  Third, we 
discuss the clinical implications of PXR’s action, including its role in drug interactions, in 
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variations in drug action in individuals, in drug resistant cancers, and as a putative target 
for the treatment of liver cholestasis.  Finally, we end by presenting future directions for 
the examination of PXR, in particular the search for potential selective PXR modulators 
(SPRMs) for a variety of clinical applications. 
 
Regulation of PXR 
 
Genetic and Functional Features 
PXR contains the conserved domain structure characteristic of nuclear receptors 
(Figure 1.1).   At its far N-terminus is a short activation function 1 (AF-1) region that 
allows the regulation of receptor action in a ligand-independent fashion.  The DNA 
binding domain (DBD) of human PXR (amino acids 41-107) contains two zinc fingers 
and binds to specific DNA response elements as a heterodimer with the retinoid X 
receptor-α (RXRα).  The sequence and structure of NR DBDs are highly conserved 
across the receptor superfamily, although monomeric variations have also been described.  
The PXR DBD also contains a reported bipartite nuclear localization sequence (Kawana, 
K., et al. 2003). The DBD and ligand binding domain (LBD) in PXR are separated by a 
hinge region (amino acids 107-141) that is considerably shorter than for other nuclear 
receptors. The PXR LBD (amino acids 141-434) contains both the ligand binding pocket 
and the ligand-dependent activation function 2 region (AF-2). The LBD of PXR is 
expected to heterodimerize with the LBD of RXRα using an extensive set of polar and 
nonpolar interactions, similar to those seen in structures of other NR LBDs with the 
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RXRα LBD (Gampe, R.T., Jr., et al. 2000a).  Conformational changes in AF-2 upon 
ligand binding are responsible for recruitment of coregulator proteins (e.g., members of 
the p160/SRC family), leading to changes in transcription of target genes (Nolte, R.T., et 
al. 1998; Renaud, J.P., et al. 1995; Xu, H.E., et al. 2002). 
Several non-synonymous SNPs in human PXR have been reported (Hustert, E., et 
al. 2001; Koyano, S., et al. 2002; Zhang, J., et al. 2001) and are labeled in Figure 1.1.  
Three coding changes within or adjacent to the PXR LBD, Val-140-Met, Asp-163-Gly 
and Ala-370-Thr, were found to alter the action of variant receptors in vitro.  One coding 
alteration detected in this analysis leads to the replacement of Arg-122 in a DNA-binding 
helix in the PXR DBD with a glutamine, which was shown to reduce DNA binding.  This 
alteration has only been found in heterozygotes with one normal PXR allele, however, 
which leads to no detectable change in response to activating ligands.  Taken together, 
these results suggest that loss of PXR action may be a clinically-relevant state for certain 
patients and pose a risk for drug toxicities and/or liver disease.   
The phosphorylation of NRs impacts many aspects of receptor activity, including 
DNA, ligand and coregulator binding, as well as the formation of receptor homo- and 
heterodimers (reviewed in (Rochette-Egly, C. 2003)).  This is not surprising given the 
well documented role of kinase/phosphatase cascades in controlling numerous 
transcription factors. NetPhos 2.0 (Blom, N., et al. 1999) was used to predict 
phosphorylation sites in PXR, and only residues with scores ≥ 0.8 are depicted in Figure 
1.1.  It was recently shown that the protein kinase C pathway appears to down-regulate 
the expression of xenobiotic metabolism enzymes, particularly cytochrome P450 3A 
isoforms, by promoting the interaction of human PXR with the transcriptional coregulator 
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NCoR while repressing the receptor’s interaction with the coactivator SRC-1 (Ding, X.S., 
et al. 2005).  Protein kinase A was shown to phosphorylate directly both the DBD and 
LBD of human PXR and, in contrast to protein kinase C, to enhance the interaction of 
PXR with corepressors in mammalian two-hybrid experiments (Ding, X.S., et al. 2005).  
Unraveling the detailed roles that specific phosphorylation sites on PXR and coregulator 
proteins play in transcriptional control and receptor trafficking remains an important area 
for future study. 
Crystal structures of the human PXR LBD have been determined alone, in 
complexes with several xenobiotics, and with a peptide fragment of the transcriptional 
coactivator SRC-1 (Chrencik, J.E., et al. 2005; Watkins, R.E., et al. 2001; Watkins, R.E., 
et al. 2003a; Watkins, R.E., et al. 2003b). Like other nuclear receptor LBDs, the PXR 
LBD contains three layers of α-helices arranged in a so-called “α-helical sandwich” that 
surrounds the receptor’s ligand binding cavity (Figures 1.2A, B) (Watkins, R.E., et al. 
2001). While most nuclear receptor LBDs contain a short, two- to three-stranded β-sheet, 
PXR extends that beta structure to a five-stranded antiparallel sheet (Chrencik, J.E., et al. 
2005; Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; Watkins, R.E., et al. 2003b).  
The PXRs contain an insert of approximately 60 amino acids (residues 175-235) that is 
novel in the nuclear receptor superfamily, but is largely conserved in the PXRs of known 
sequence.  Exceptions to this rule are certain PXR splice variants that lack this insert and 
are considerably less promiscuous in their response to ligands (Kliewer, S.A., et al. 
1998).  
The novel sequence insert in the PXR LBD is partially disordered in the structures 
determined to date; amino acids between residues 178 to 191 have consistently been too 
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mobile to be visualized in numerous crystal structures.  The remaining residues in this 
insert, however, are ordered and fold into a distinct α−β-turn-β motif adjacent to the 
receptor’s ligand binding pocket (Figures 1.2A, B).  The novel α2 extends along the 
“bottom” of the ligand binding pocket, and is a particularly mobile region that is key to 
the receptor’s broad response to activating ligands (as discussed below).  The two 
additional β-strands, β1 and β1’, generate the longer β-sheet in PXR.  These β-strands 
also interact between LBD monomers to create a novel homodimeric complex that has 
been observed in all PXR structures to date (Figure 1.2A) (Chrencik, J.E., et al. 2005; 
Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; Watkins, R.E., et al. 2003b). The 
homodimer formed by the PXR LBD does not interfere with the heterodimer it is 
expected to form with the RXRα LBD.  The amino acids involved in this homodimer 
interface are conserved in the PXRs of known sequence and are also unique to the PXRs 
within the NR superfamily.  Studies are currently ongoing to determine the biological 
relevance of this homodimer, although initial results indicate that the formation of this 
higher-order structure in PXR is central to its transcriptional activity (Noble and Redinbo, 
unpublished).  
The ligand-binding pocket is large, flexible, and capable of varying in volume 
between 1,280 and >1,600 Å3 in the crystal structures of apo and ligand-bound 
complexes reported to date.  Thus, PXR is on par with the largest known NR ligand 
binding cavity, which is 1,619 Å3 for the fatty acid-binding receptor PPARγ (Nolte, R.T., 
et al. 1998).  The receptor’s cavity is predominantly hydrophobic but contains eight polar 
residues distributed throughout the surface of the pocket (Watkins, R.E., et al. 2001). In 
this way, PXR’s pocket reflects the general character of the xenobiotic ligands to which it 
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binds, which are typically lipophilic compounds with a limited number of polar groups 
(Lipinski, C.A., et al. 2001).  A more detailed discussion of the recognition of ligands by 
PXR is provided below.  The PXR LBD ends with a final short α−helix termed αAF, as it 
generates a key part of PXR’s AF-2 motif.  As in other nuclear receptors, the interacting 
region of the transcriptional coactivator SRC-1 (yellow in Figure 1.2B) binds in a groove 
formed with residues from αAF, α3, and α4 (Watkins, R.E., et al. 2003a). The invariant 
leucines in this coactivator LxxLL motif (where x is any residue) fit into hydrophobic 
pockets in the receptors AF-2 region, and the short helix formed by the LxxLL sequence 
is capped by a glutamic acid and lysine residue from PXR around the N- and C-terminus, 
respectively, of the helix (Figure 1.2C). 
 
Ligand Binding 
PXR is distinct in the nuclear receptor superfamily because it responds 
promiscuously to a wide variety of chemically-distinct ligands ranging in mass from 232 
Da (phenobarbital) to >800 Da (taxol, rifampicin) (Bertilsson, G., et al. 1998; Jones, S.A., 
et al. 2000; Kliewer, S.A., et al. 1998; Lehmann, J.M., et al. 1998; Synold, T.W., et al. 
2001) (Figure 1.3A).  While most compounds act as agonists, a small number of 
chemicals with potential antagonist activity have been reported, including ecteinascidin 
743 (ET-743) (Synold, T.W., et al. 2001) and ketoconazole (Takeshita, A., et al. 2002).  
Although each PXR isoform examined to date is promiscuous, a clear pattern of inter-
species differences in specificity has been observed.  For example, mouse PXR is not 
activated efficiently by SR12813 (a cholesterol-lowering compound), but human and 
rabbit PXR are; mouse PXR, in contrast, is activated by PCN (pregnenolone 16α-
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carbonitrile), while human and rabbit PXR are not (Blumberg, B., et al. 1998; Jones, 
S.A., et al. 2000; Lehmann, J.M., et al. 1998).  The LBDs of the PXRs vary considerably 
in sequence between related mammalian isoforms (e.g., by as much as 76% between 
human and rat (Jones, S.A., et al. 2000)), which is uncommon in the NR superfamily.  It 
is clear that a small number of amino acid changes are responsible for this “directed 
promiscuity” observed between the PXRs of mammalian species.  For example, the 
human residue (Leu308) or group of three residues (Gln317, Leu324, and Tyr328) 
confers rifampicin sensitivity to rat PXR (Tirona, R.G., et al. 2004). These residues are 
located at the end of β4, in α7, and in the unstructured loop between these two secondary 
structure elements.   
It has been speculated that a common ancestral ligand exists that regulated the 
action of the first PXR.  Krasowski and colleagues recently suggested that endogenous 
bile acids may have been the original ligands that drove PXR’s evolution and species-
specific variability (Krasowski, M.D., et al. 2005)  Indeed, several groups have shown 
that PXR plays a crucial role in detecting the build-up of potentially toxic bile acids and 
up-regulating the expression of bile acid metabolizing enzymes to protect the liver and 
other tissues.  These data support PXR’s adopted role as a molecular sentinel that detects 
the presence of potentially harmful endobiotic and xenobiotic compounds. 
The clogP characteristics of PXR ligands were examined to determine if the 
receptor functions simply as a “hydrophobic sink”, where interactions between the 
receptor and ligand are driven by non-specific hydrophobic binding to the PXR pocket, or 
whether the receptor has more selective characteristics in ligand binding.  The 
hydrophobicity of known PXR ligands (as represented by clogP) was plotted as a 
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function of ligand molecular weight, and compared to a set of 10,000 compounds with 
drug-like qualities (Figure 1.3B).  PXR ligands did not cluster in a particular region of 
this plot, but instead appear to sample many regions of this drug-like space.  PXR is not 
the transcription factor equivalent of a serum albumin, which binds non-specifically to an 
extremely diverse set of chemicals in circulating plasma.  Indeed, functional and 
structural studies have shown that the PXRs from distinct species exhibit promiscuity 
directed toward distinct regions of endobiotic and xenobiotic chemical space.  
Several crystal structures show ligand binding to PXR induces significant 
conformation changes in the pocket of the receptor (Figure 1.4A). While most of the 
amino acid side chains that line the ligand binding pocket of PXR remain in a consistent 
position in the apo (unliganded) and numerous ligand-bound structures, a small number 
of residues undergo significant rotamer changes or shifts in position in both main chain 
and side-chain atoms (Figure 1.4B). For example, the side chain of His-407 undergoes 
rotamer shifts of up to 7 Å between different PXR LBD structures, while both the side 
chain and main chain atoms of Leu-209 have also been observed to shift translationally in 
position by up to 7 Å.  Both residues have been found by mutagenesis to be critical to the 
receptor’s response to distinct ligands (Chrencik, J.E., et al. 2005; Watkins, R.E., et al. 
2003a; Watkins, R.E., et al. 2003b).  An examination of Figure 1.4B reveals that most of 
the mobile residues in PXR (in particular residues 206-211) reside in the sequence insert 
novel to the PXRs.  
Flexibility is critical to PXR’s promiscuity by enabling the receptor to change 
shape to accommodate structurally-distinct chemicals.  For example, the small agonist 
SR12813 was initially shown through detailed crystallographic studies to bind to PXR in 
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numerous distinct orientations at once (Figure 1.4B) (Watkins, R.E., et al. 2001).  When 
the LxxLL motif of the transcriptional coactivator SRC-1 binds to the surface of PXR, 
however, this same agonist shifts to a single, unique binding orientation.  These results 
suggest that the receptor’s inherent flexibility (or “breathing”) can occur even with a 
small ligand bound, but that interactions with a coactivator partially lock the receptor to 
restrict such flexibility.  Numerous other ligands have been examined in complex with 
PXR, including the St. John’s wort compound hyperforin, the antibiotic rifampicin, as 
well as additional small agonists and endogenous steroids.  In the structure of each 
complex, the ligand binding pocket changes shape to accommodate the distinct features 
of the ligand.  The most dramatic example of the “induced fit” nature of PXR is its 
interaction with the macrolide rifampicin.  Initial PXR structures suggested that the 
receptor’s pocket would have to change shape and size significantly to accommodate this 
823 Da ligand.  Rifampicin binding causes the bottom, flexible portion of the binding 
cavity, in particular the regions on the 60 amino acid insert novel to PXR, to become 
disordered and not to be observed in the electron density maps of this structure.  These 
results suggest that the receptor is capable of activating transcription even if portions of 
its ligand binding domain are relatively unstructured.  This appears to be a key feature of 
this xenobiotic receptor’s ability to respond promiscuously to small and large compounds 
that vary in chemical nature and structure. 
 
Subcellular Localization 
Previous reports based on GFP-tagged human PXR (hPXR) localization 
experiments and immunocytochemistry of hPXR in cells indicated that PXR always 
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localized to the nucleus regardless of the presence or absence of ligand (Koyano, S., et al. 
2004; Sueyoshi, T., et al. 2001). Other groups, however, have detected ligand-dependent 
translocation of PXR from the cytoplasm to the nucleus in the liver of mice treated with 
PCN (Kawana, K., et al. 2003; Squires, E.J., et al. 2004). Squires and colleagues further 
showed that PXR binds in the cytoplasm to heat shock protein 90 (Hsp90) and the 
constitutive active/androstane receptor retention protein (CCRP) in HepG2 cells, and that 
these proteins assist with (but do not follow) the receptor in its translocation to the 
nucleus upon ligand binding (Squires, E.J., et al. 2004).  Determining whether and to 
what degree these interactions with known NR binding proteins in the cytoplasm impact 
PXR’s promiscuity in response to ligands is an important area for future study.   
 
DNA Binding  
PXR forms a heterodimer with RXRα upon binding to specific repeats of 
AG(G/T)TCA in the promoter regions of genes (Blumberg, B., et al. 1998; Lehmann, 
J.M., et al. 1998; Mangelsdorf, D.J., et al. 1995).  The DBDs of both receptors are 
expected to be highly similar in structure to the RXRα DBD, which is a double zinc-
finger motif that contacts DNA in a sequence-specific manner.  The response elements 
are arranged as direct repeats (both sequences in the same 5’-3’ direction) with 3 to 5 
bases separating DBD binding sites (DR-3, DR-4, and DR-5 elements), as well as everted 
repeats (with the beginning of each sequence in proximity) separated by six or eight bases 
(ER-6 and ER-8, respectively) (Blumberg, B., et al. 1998; Kast, H.R., et al. 2002; 
Lehmann, J.M., et al. 1998). Because PXR response elements vary between direct and 
everted repeats, the DBDs of the two receptors within the physiologically relevant 
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heterodimer must be able to reorient themselves to contact efficiently these distinctly 
arranged response elements.  Since the LDBs of PXR and RXRα are expected to form 
only a single type of heterodimeric complex, the regions that connect the DBDs and 
LBDs must allow significant flexibility to allow relative variations in DBD positions.  
There is evidence that the PXR-RXRα heterodimer recruits distinct transcriptional 
coregulators depending on the nature of the ligand and response element bound (see 
below).  The control of gene expression by PXR appears to involve subtleties beyond the 
well established canonical steps in NR function – DNA, ligand and coregulator binding. 
 
Coregulator Binding  
In contrast to well-characterized receptors like the estrogen receptor isoforms, the 
complexes PXR forms with partner proteins to control the expression of target genes is 
poorly understood. A simplified prototypical model of regulation would suggest that PXR 
is retained in the cytoplasm until some signal causes a translocation to the nucleus and 
the formation of a heterodimer with RXRα on target XREs. In the absence of agonist or 
the presence of antagonist, corepressors (e.g., NCoR and SMRT) are thought to bind to 
the receptor and deacetylate histones, preventing transcription of the target genes. In the 
presence of an activating ligand, the receptor-agonist complex can associate with 
coactivators (e.g. SRC-1) and allow large transcription complexes to form on target gene 
promoters. Either the coactivators or the proteins they recruit have histone acetylase 
activity, leading to chromatin decondensation and gene transcription. Such a simplified 
model is complicated by the fact that receptor activity is also influenced by promoter 
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location, the nature of the agonist, and the expression levels of coregulators in particular 
tissues or cell lines.  
Early studies determined via co-immunoprecipitation that PXR bound SRC-1 
(Kliewer, S.A., et al. 1998). Subsequent data on coactivator interactions were derived 
largely from directed yeast and mammalian two-hybrid studies. In a yeast two-hybrid 
experiment, Masuyama et al. confirmed that, in the presence of nonylphenol or phthalic 
acid, full length mouse PXR interacts with steroid receptor coactivator-1 (SRC-1) and 
receptor interacting protein 140 (RIP-140), but not suppressor for gal-1 (SUG1). 
(Masuyama, H., et al. 2000) In the presence of progesterone, dexamethasone or 
pregnenolone, mPXR interacted with SRC-1, RIP140, and SUG1. (Masuyama, H., et al. 
2001) As discussed above, the cross-species specificity of PXR emphasizes the 
importance of performing experiments to confirm these interactions for human PXR. 
Most studies to date of coregulator interactions with human PXR employ only the 
receptor’s LBD (fused to Gal4 or VP16), and several have confirmed PXR’s interaction 
with SRC-1 (Synold, T.W., et al. 2001; Takeshita, A., et al. 2001; Takeshita, A., et al. 
2002; Wentworth, J.M., et al. 2000). One of these studies also demonstrated interactions 
between hPXR LBD and glucocorticoid receptor interacting protein 1 (GRIP1), human 
activator for thyroid hormone and retinoid receptors (ACTR), and human vitamin D 
receptor-interacting protein complex component (DRIP205, also called PBP and 
TRAP220) in the presence of paclitaxel or docetaxel (Synold, T.W., et al. 2001).  A recent 
study demonstrated that full length human PXR interacts with PGC-1α, and subsequently 
interferes with HNF-4 signaling (Bhalla, S., et al. 2004).  Building up these more intricate 
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complexes, and elucidating the effects they have on signaling by other transcriptional 
systems, remains an exciting area for future study. 
PXR and the related constitutive androstane receptor (CAR) both possess 
substantial basal activity. CAR plays an overlapping but distinct role in regulating the 
expression of genes involved in xenobiotic metabolism, as well as cholesterol and 
endobiotic homeostasis.  While the structural basis of CAR’s constitutive activity has 
recently been examined in detail (Moore, D.D. 2005; Shan, L., et al. 2004; Suino, K., et 
al. 2004; Xu, R.X., et al. 2004), it is not so clear for PXR.  Indeed, site-directed mutations 
located far away from the AF-2 region in PXR have been shown to enhance (and in some 
cases to repress) the basal activity of the receptor.  A structural explanation for these 
effects has remained elusive. Recent work by Ueda et al., however, showed that a 
conserved threonine (Thr-248) interacts with a threonine in the αAF of the AF-2 region to 
confer constitutive activity (Ueda, A., et al. 2004). This is an important step forward in 
understanding the basal activity of PXR, and the next challenge will be to extend the 
analysis to regions of the receptor seemingly removed from the αAF and AF-2 area.  
The interaction of PXR with corepressors is more poorly understood than its 
interaction with coactivators. SMRT and NCoR, known corepressors of nuclear receptor 
transcription, have been tested in vitro for their ability to form complexes with PXR. 
Synold et al. observed that PXR interacted with both SMRT and (to a lesser extent) 
NCoR in the absence of ligand, and different ligands had differing abilities to prevent 
these interactions (Synold, T.W., et al. 2001). Subsequently, two other groups examined 
corepressor effects on the CYP3A4 promoter in specific cell lines (Takeshita, A., et al. 
2002; Zhou, C.C., et al. 2004). In HepG2 cells (but not CV-1 cells), PXR showed 
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increased interactions with SMRT in the presence of the agonist rifampicin, and these 
interactions lead to decreased basal and ligand-induced activity on the CYP3A4 promoter 
(Takeshita, A., et al. 2002). In contrast, NCoR was responsible for repression of 
tocotrienol-induced CYP3A4 gene expression in LS180 cells (Zhou, C.C., et al. 2004), 
but a separate mechanism appeared to be required for the repression of UGT1A1 and 
MDR1 expression in the same cell line (Zhou, C.C., et al. 2004). These findings support 
the emerging conclusion for many members of the NR family that regulation is a highly 
complex ligand- and tissue-specific process. 
 
Degradation pathways 
 Degradation pathways play important roles in nuclear receptor function via 
modulating protein levels and mediating receptor turnover. Degradation of PXR has not 
been studied in-depth; however, preliminary data indicate that PXR is degraded by the 
proteasome.  PXR was found to interact with SUG-1, a component of the 26S proteasome 
complex, in the presence of progesterone but not in the presence of endocrine disrupting 
chemicals (Masuyama, H., et al. 2000). Further investigation confirmed that the 
proteasome is responsible for PXR degradation, and that ligands that do not enhance 
PXR’s interaction with SUG1 (e.g., non-natural endocrine disrupting chemicals) strongly 
block degradation of PXR (Masuyama, H., et al. 2002). Similar to the recruitment of 
coregulators, PXR’s interactions with SUG1 and the receptor’s degradation by the 
proteasome appear to be complex processes that warrant continued investigation. 
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Regulation by PXR 
 
Tissue Expression Patterns of PXR 
The function of the PXR receptor is linked to its expression pattern in different 
tissues.  Originally, Northern blots detected human PXR expression in liver, colon, and 
small intestine (Lehmann, J.M., et al. 1998), sites associated with detecting and 
combating xenobiotics and potentially toxic endobiotics related to bile acid and 
cholesterol homeostasis. RT-PCR studies have confirmed presence of PXR mRNA in 
these three tissues, in addition to finding expression in stomach, fetal liver, thalamus, 
spinal cord, and low levels in heart, bone marrow, adrenal gland, pons and medulla 
(Lamba, V., et al. 2004). Dotzlaw and colleagues demonstrated that PXR is expressed in 
breast tumors and surrounding normal breast tissue (Dotzlaw, H., et al. 1999), and 
Masuyama and colleagues have shown that PXR is up-regulated in endometrial cancer 
cell lines (Masuyama, H., et al. 2003).  These emerging results begin to link PXR to the 
progression and drug resistance of neoplastic tissues, a potentially important area of 
continued study (see “Clinical Implications” below) (Masuyama, H., et al. 2003; 
Masuyama, H., et al. 2005). 
 
Genes Regulated by PXR 
The list of genes regulated by PXR continues to grow, and now includes not only 
systems related to drug and xenobiotic metabolism but also those central to cholesterol 
and bile acid metabolism and excretion.  The first list of gene products shown to be 
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regulated by PXR were CYP3A1 and CYP3A2 (Kliewer, S.A., et al. 1998), for mouse 
PXR, and subsequently CYP3A4 for human PXR (Lehmann, J.M., et al. 1998).  More 
comprehensive systematic studies followed these initial reports and showed that human 
PXR regulates the expression of numerous gene products involved in all phases of 
xenobiotic metabolism and excretion (Maglich, J.M., et al. 2002; Rosenfeld, J.M., et al. 
2003; Watkins, R.E., et al. 2003b).  Phase 1 (oxidation) drug metabolism gene products 
regulated by PXR include numerous cytochromes P450, aldehyde and alcohol 
dehydrogenases, carboxylesterases, and several enzymes related to heme production and 
support of the P450 reaction cycle, such as aminolevulonic acid synthase and P450 
oxidoreductase (Maglich, J.M., et al. 2002; Rosenfeld, J.M., et al. 2003; Watkins, R.E., et 
al. 2003b).  In particular, the promiscuous and highly expressed human cytochrome P450 
3A4 isoform (CYP3A4) is efficiently up-regulated by PXR, so much so that PXR has 
been termed a master regulator of CYP3A4 expression in human tissues.  This CYP 
metabolizes over 50% of human therapeutic compounds (Maurel, P. 1996).  Phase 2 drug 
metabolism gene products, which are involved in conjugating xenobiotics, are also 
regulated by PXR, including the abundant and highly active UDP-
glucuronosyltransferases, as well as sulfotransferases and glutathione S-transferases 
(Dunn, R.T., et al. 1999; Falkner, K.C., et al. 2001; Rosenfeld, J.M., et al. 2003; Runge-
Morris, M., et al. 1999; Watkins, R.E., et al. 2003b).  Drug efflux pumps, central to Phase 
3 “elimination” stage of drug metabolism, are also up-regulated by PXR, including 
numerous ATP-binding cassette integral membrane pumps of the multidrug resistant 
(MDR) family (Dussault, I., et al. 2001; Geick, A., et al. 2001; Kast, H.R., et al. 2002; 
Rosenfeld, J.M., et al. 2003; Staudinger, J.L., et al. 2001; Synold, T.W., et al. 2001; 
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Watkins, R.E., et al. 2003b).  Taken together, these results support the central role PXR 
plays in coordinating the up-regulation of the complete process of drug metabolism in 
response to activating xenobiotic agonists. 
PXR’s original adoption as a receptor that responds to endogenous pregnanes has 
also lead to detailed studies of its role in endobiotic detection and metabolism.  Initial 
experiments had identified Cyp7A and Oatp2 (Staudinger, J.L., et al. 2001; Xie, W., et al. 
2001b) as target genes regulated by PXR, results that were supported and expanded by 
more comprehensive subsequent studies.  PXR clearly plays several important roles in 
detecting oxysterols and bile acids, and is central to the proper maintenance of cholesterol 
homeostasis and fatty acid metabolism.  Related gene products known to be regulated by 
PXR include fatty acid and HMG CoA synthases, organic anion transporters, and 
cytochromes P450 involved in cholesterol and bile acid metabolism (Dussault, I., et al. 
2003; Goodwin, B., et al. 2003; Rosenfeld, J.M., et al. 2003; Xie, W., et al. 2003).  In 
particular, it was shown that PXR’s ability to down-regulate the expression of CYP7A in 
response to rifampicin involved the displacement of the transcriptional coactivator PGC-
1α from the related HNF4 nuclear receptor, and direct binding of HFN4 by PXR (Bhalla, 
S., et al. 2004; Li, T.G., et al. 2005).  These data further indicate that PXR’s role in 
controlling gene expression involves mechanisms beyond the fundamental “ligand 
binding and coregulator recruitment” paradigm.  
It is interesting to note that PXR regulates the expression of the related CAR 
receptor in response to agonists (Maglich, J.M., et al. 2002; Rosenfeld, J.M., et al. 2003). 
CAR plays overlapping but distinct roles in regulating key xenobiotic and endobiotic 
metabolism pathways. In addition to the well established drug and endobiotic metabolism 
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systems regulated by PXR, other intriguing genes linked to PXR regulation include the 
insulin-regulated gene pathways, the Huntington protein, and the oncogene A-raf 
serine/threonine kinase (Rosenfeld, J.M., et al. 2003).  These results indicate that PXR 
likely plays important, but relatively unexamined, roles in numerous human disease 
states. 
 
Clinical Implications of PXR Action 
 
Drug-Drug Interactions 
Activation of PXR by clinical drugs, herbal remedies, and vitamin supplements 
has been linked to potentially dangerous drug-drug interactions.  Perhaps the best 
characterized example of this involves the activation of PXR by hyperforin, the active 
agent of the unregulated herbal antidepressant remedy St. John’s wort.  The use of St. 
John’s wort had been shown to reduce the  serum levels of several clinical therapeutics, 
including antivirals used to treat HIV and immunosuppressant agents prescribed to organ 
transplant patients (Piscitelli, S.C., et al. 2000; Ruschitzka, F., et al. 2000).  Hyperforin 
was found to be a potent PXR agonist (with an EC50 of 32 nM) and to up-regulate the 
expression of a variety of drug metabolism and excretion genes in primary human 
hepatocytes, including significant inductions of CYP3A4 expression (Moore, L.B., et al. 
2000; Watkins, R.E., et al. 2003b; Wentworth, J.M., et al. 2000).  This provided a clear 
molecular link between St. John’s wort, the activation of drug metabolism pathways, and 
the unwanted elimination of therapeutic agents.  In addition to rifampicin, which is a well 
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established “inducer” of drug metabolism systems, the list of ligands that activate PXR 
now includes the chemotherapeutic agents paclitaxel (Synold, T.W., et al. 2001) and 
cisplatin (Masuyama, H., et al. 2005).  The scope has widened to include vitamins with 
the demonstration that both vitamin E (tocopherol) and vitamin K2 are activators of 
PXR-mediated expression of target genes (Landes, N., et al. 2003; Tabb, M.M., et al. 
2003).  Taken together, these observations signal that patients and caregivers should 
continue to be aware of potentially life-threatening drug-drug and unregulated 
supplement-drug interactions involving the activation of PXR.  
 
Individual Responses to Therapeutics 
The identification of non-synonymous polymorphisms in the PXR gene in human 
populations has validated the role this receptor plays in individual sensitivities to clinical 
drugs. It is conceivable that as personalized approaches to medical treatments evolve 
(ones in which the genetic background of the patients is considered), characterizing 
potential variations in PXR sequence would become an important test to identify patients 
at risk for adverse reactions to drugs or drug combinations. As a first pass, simple 
modifications to the erythromycin breath test procedure, which assesses CYP3A4 
activity, can provide a non-invasive measure of PXR’s action in patients (Hariparsad, N., 
et al. 2004).  In situations where altered PXR function is suspected, a more careful 
examination of the PXR gene could be performed to identify SNPs or other variations in 
DNA sequence. In addition, tissue-specific splice variants of PXR could impact 
therapeutic efficacy and tolerance (Gardner-Stephen, D., et al. 2004), so the continued 
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study of such variations may also improve our ability to avoid unwanted reactions to 
clinical treatments.   
 
Cholestasis 
PXR has been known since its adoption as a pregnane sensor to respond to 
endogenous compounds based on the cholesterol and/or steroid scaffold, including 
oxysterols and bile acids.  Now numerous lines of evidence support PXR’s role in 
detecting endogenous bile acids and cholesterol precursors in vivo.  For example, 
increased PXR activity has been shown to protect the liver and other tissues from 
exposure to excess dietary bile acids and to the build-up of cholesterol precursors caused 
by the elimination of key enzymes in the cholesterol homeostasis pathways (Goodwin, 
B., et al. 2003).  The impact of a high cholesterol and cholic acid diet of PXR knockout 
mice was recently shown to cause lethal damage to the liver in 100% of these animals, 
but not to exert a similar effect on wild-type mice (Sonoda, J., et al. 2005).  These data 
highlight PXR’s importance in responding to the presence of toxic levels of bile acids and 
other potentially harmful endobiotics.  Indeed, the PXR agonist rifampicin and the herbal 
remedy St. John’s wort (containing the potent PXR agonist hyperforin) have been used to 
treat cholestatic liver disease, which is associated with the build up of bile acids and other 
endogenous compounds (Bachs, L., et al. 1992; Ozturk, Y., et al. 1992).  Identifying 
additional or improved PXR activators may provide a novel set of tools to treat 
cholestasis. 
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Cancer 
PXR plays an obvious role in cancer treatment because it is activated by 
chemotherapeutic compounds like paclitaxel (Synold, T.W., et al. 2001) and cisplatin 
(Masuyama, H., et al. 2005).  Indeed, the up-regulation of drug metabolism and excretion 
genes by the receptor is one of the reasons that high doses of such antineoplastic agents 
are required for clinical efficacy.  It would be advantageous to identify lead compounds 
or codrugs that limit PXR’s activation of xenobiotic metabolism pathways to avoid the 
toxicities and potential drug-drug interactions associated with anticancer drugs.  
Beyond this connection to cancer treatment, and more basic link between PXR 
and cancer development is emerging.  In PXR’s role as a bile acid sensor, the receptor 
protects tissues from the potentially toxic effects of these compounds, which are known 
to promote colon cancer (Uppal, H., et al. 2005).  PXR also appears to be manipulated by 
cancerous cells to promote tumor growth.  Dotzlaw et al. showed in 1999 that both the 
normal and shorter splice variant of PXR (PXR.2, which lacks a portion of the sequence 
insert in the receptor that is linked to its promiscuity) are expressed in human breast 
cancer cells (Dotzlaw, H., et al. 1999).  Indeed, these authors found that PXRs isoforms 
were more abundantly expressed in breast cancer cell lines that lacked expression of the 
estrogen receptor (ER).  These data suggest that local concentrations of endogenous 
compounds, as well as therapeutic agents, may be significantly altered in tumor cells by 
the overexpression of PXR.   
A related pattern of PXR up-regulation combined with ER down-regulation was 
identified in endometrial cancer cells but not in normal cells from the same tissue 
(Masuyama, H., et al. 2003), suggesting again that PXR provides a growth advantage to 
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neoplastic cells by processing steroid-like compounds and/or xenobiotics.  Indeed, in a 
follow-up paper, the same group has recently examined the effect of steroids, endocrine 
disrupting chemicals (EDCs), and anticancer agents on PXR-mediated expression from 
response elements derived from two different promoters, MDR1 and CYP3A4 
(Masuyama, H., et al. 2005).  Remarkably, they found that the steroid/EDC compounds 
like estradiol and phthalate utilized the CYP3A4 promoter more efficiently than MDR1, 
and conversely that the anticancer agents paclitaxel and cisplatin preferred the MDR1 
over the CYP3A4 promoter.  The molecular basis of this effect was traced to preferential 
recruitment of specific coactivators in a promoter- and ligand-specific fashion.  Estradiol 
and phthalate exhibited a clear preference for the coactivator SRC-1 on the CYP3A4 
promoter, while the anticancer drugs strongly recruited AIB-1 to the MDR1 promoter.  
These results and related data show that different ligands recruit different coregulators to 
the surface of PXR, and that these differential associations are promoter-specific (Song, 
X.L., et al. 2004).  These results also indicate that opportunities exist for the 
identification of selective PXR agonists that may be useful in the direct treatment of 
cancer, or in tuning the efficacy of other chemotherapeutic compounds. 
 
Future Directions 
 
While our understanding of the regulation and action of PXR grows, both on the 
structural and functional level, several important areas of future study have emerged.  The 
structure of the full-length PXR receptor in a ternary complex with RXRα and DNA 
remains a critical target for crystallographic studies.  Such a structure would greatly 
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advance our understanding of nuclear receptor function in general, including how the 
flexible hinges between the receptors’ DNA binding and ligand binding domains allow 
the heterodimer to contact both direct and everted regulatory elements.  Initial strides 
have been made in examining the role that phosphorylation plays in PXR function, but 
clearly more work needs to be done on PXR and other members of the NR superfamily to 
elucidate how phosphorylation cascades impact receptor stability and function.  In 
addition, while enticing recent work indicates that the activation of PXR by different 
ligands on different promoter elements leads to the recruitment of distinct transcriptional 
coactivators, it will be of tremendous interest to elucidate the role that such fine levels of 
ligand control play in PXR’s function in numerous distinct tissues.  Finally, the 
differential up-regulation of PXR in certain human cancers, as well as our growing 
understanding of the manner in which the receptor is activated by ligands, suggests that 
selective PXR modulators (SPRMs) might be of considerable use in treating neoplastic as 
well as metabolic diseases.  PXR has moved quickly from an orphan receptor to an 
established transcriptional regulator and putative drug target.  It seems clear, however, 
that we are only beginning to unravel the function and therapeutic potential of this 
unusual member of the nuclear receptor superfamily. 
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 Figure 1.1. Cartoon depiction of human PXR domain 
structure and important features. The domain structure of 
human PXR is presented, including the N-terminal ligand-
independent activation function 1 (AF-1), the DNA binding 
domain (DBD), the relatively short hinge region, and the ligand 
binding domain (LBD), which contains the ligand-dependent 
activation function 2 (AF-2).  Reported spice variants and 
putative phosphorylation sites are depicted with diamonds and 
asterisks, respectively. 
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Figure 1.2A. PXR LBD homodimer. The homodimer of the human PXR ligand binding 
domain (LBD) as observed in the crystal structures reported to date. 
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Figure 1.2B. Structure of PXR LBD bound to SR12813 and SRC-1 peptide. A 
monomer of the human PXR LBD in complex with the small cholesterol-lowering 
agonist SR12813 (purple) and a fragment of the human transcriptional coactivator SRC-1 
(yellow).  Amino acids 178-191 of the LBD are disordered in this structure. 
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Figure 1.2C. Interaction of SRC-1 peptide with PXR LBD charge-clamp. A fragment 
of human SRC-1, containing three leucines of an LxxLL motif, stabilized on the surface 
of the human PXR LBD by the charge clamp formed by Lys-259 and Glu-427, which 
hydrogen bond to the main-chain of the coactivator helix. 
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Figure 1.3A. PXR ligands. Endogenous and xenobiotic compounds of various sizes and 
shapes are ligands for PXR. 
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Figure 1.3B. The hydrophobicity versus molecular weight of PXR ligands compared 
to a database of drug-like molecules. The hydrophobicity (clogP) versus molecular 
weight of PXR ligands (red circles) compared to a database of 10,000 drug-like 
molecules (blue circles).  The common limits in size and logP characteristics associated 
with successful drugs are shown. 
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Figure 1.4A. PXR accommodates different ligands by changing the shape of the 
ligand binding pocket. The molecular surface of the PXR ligand binding pocket has 
been observed in several crystal structures to change in shape to accommodate distinct 
ligands.   
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Figure 1.4B. PXR pocket side chains that shift. Amino acids side chains that line the 
PXR pocket have been observed to be rigid (bold), to exhibit small rotamer changes 
(italics), or to undergo relatively large rotamer changes or shifts in position (italics and 
underlined with magnitudes indicated). 
 
Chapter 2 
Discovery of a Consensus Motif in PXR LBD-Interacting Peptides and Production 
of Full-Length PXR for Future Studies 
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Abstract 
 
The nuclear pregnane X receptor (PXR) regulates expression of many genes 
essential in mammalian drug metabolism including cytochrome P450-3A4 (CYP3A4), 
which degrades more than 50% of all prescription drugs. PXR is, like most nuclear 
receptors, a ligand-activated transcription factor, but it is unique in that it responds to a 
wide variety of structurally distinct compounds. Though sometimes PXR is represented 
as a binary switch, either on or off, variable modulation of PXR may lead to a wider 
range of responses via differential recruitment of transcriptional coregulators. In work 
presented here, GRIP-1 and PGC-1α were shown to coactivate PXR transcriptional 
activity on a DR-4 promoter and XREM-CYP3A4-luciferase promoter in both HepG2 
and HeLa cells. This study then investigated whether PXR LBD in complex with 
different ligands recruits distinct peptide sequences by mapping the surfaces that PXR 
LBD presents in the presence of different ligands using phage-display and verifying these 
interactions in mammalian two-hybrid screens. Because portions of the N-terminal 
domain as well as the DNA it binds to are known to influence LBD conformation and 
coactivator binding preference, it is necessary to study this pathway in the context of the 
full-length receptor; therefore, full-length PXR was also expressed and purified for use in 
determining whether full-length PXR exposes novel surfaces (not present in the LBD 
alone) involved in tissue-specific protein-protein interactions. Additionally, a small 
intestine library was generated in a T7 bacteriophage system for use in determining full-
length PXR-protein interactions and analyzing whether they differ between libraries 
generated from specific tissues. Attempts can be made to link these key surfaces of PXR 
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to function(s) by using peptides identified in this study to block PXR interaction with any 
proteins identified in the future from the T7 libraries. The preliminary results of these 
experiments as well as continued experiments with reagents generated in this study are 
necessary to understand clearly the regulatory mechanisms of PXR and how they 
influence drug efficacy or drug-drug interactions.  
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Introduction 
 
PXR as a target for evaluating therapeutics  
The pregnane X receptor (PXR) is a nuclear receptor that regulates expression of 
many genes essential in mammalian drug metabolism, including members of the 2B and 
3A subfamilies of cytochrome P450s (CYP2B and CYP3A) and the xenobiotic efflux 
pump MDR1 (human multidrug resistance 1 protein). (Goodwin, B., et al. 2002) The 3A4 
isoform is the predominant CYP expressed in the human adult liver and small intestine; 
this isoform is known to metabolize more than 50% of prescription drugs and is thought 
to be the key player in drug-drug interactions. (Guengerich, F.P. 1999; Li, A.P., et al. 
1995; Maurel, P. 1996; Michalets, E.L. 1998) For instance, it is clear that activation of 
PXR by hyperforin (the psychoactive constituent of St. John’s Wort) is responsible for 
decreased serum levels of vital drugs such as cyclosporin and indinavir. (Moore, L.B., et 
al. 2000) Additionally, in patients taking the antibiotic rifampicin, PXR has been 
implicated in increased clearance of cyclosporin A, oral contraceptives, glucocorticoid 
derivatives, and calcium channel blockers. (Takeshita, A., et al. 2002) Regulation of 
important xenobiotic metabolism genes by PXR has been well-documented; however, the 
mechanisms regulating PXR are poorly understood. With an increasing number of 
diseases necessitating combination therapies (AIDS, cancers, etc.) and rampant self-
medication with over-the-counter remedies, it is critical to characterize the PXR signaling 
pathway.  
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Overview of PXR  
Originally an orphan receptor, PXR was cloned prior to assignment of its cognate 
ligand or biological function, but was soon found to respond to the endogenous pregnanes 
and exogenous drugs. Like other nuclear receptors, PXR contains a highly conserved 
DNA binding domain (DBD) with two zinc finger domains and a ligand binding domain 
(LBD) in the C-terminal region. PXR is known for its ability to bind a wide variety of 
structurally distinct compounds (with ligands ranging in size from 200-850 Da). Though 
PXR is highly promiscuous, it does show inter-species differences in specificity: for 
example, mouse PXR is not activated efficiently by SR12813 (a cholesterol drug), but 
human and rabbit PXR are; and mouse PXR is activated by PCN (pregnenolone 16α-
carbonitrile), while human and rabbit PXR are not. (Watkins, R.E., et al. 2001) 
The structure of the human PXR LBD has been determined in the absence of 
ligand and in the presence of hyperforin (Watkins, R.E., et al. 2003b) or SR12813 and a 
peptide fragment of coactivator SRC-1 (Watkins, R.E., et al. 2001; Watkins, R.E., et al. 
2003a). The structure is shown in Figure 1.2B; it contains ten alpha helices and a five-
stranded beta sheet (in contrast to the typical nuclear receptor’s three-stranded beta 
sheet). (Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; Watkins, R.E., et al. 
2003b) The ligand-binding pocket is very large (1100-1500Å3) and predominantly 
hydrophobic with the eight polar residues evenly distributed throughout the twenty 
hydrophobic residues that line the pocket. (Watkins, R.E., et al. 2001) The coactivator 
fragment (cyan in Figure 1.2B) binds in a groove formed with residues from the AF-2 
helix (αAF; activation function), α3, and α4; the coactivator binds adjacent to the AF-2 
helix that is responsible for ligand-dependent transcriptional activation (labeled αAF in 
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Figure 1.2B). The additional beta strands and the novel α2 are part of a 60 residue insert 
not found in sequences of other nuclear receptors. (Watkins, R.E., et al. 2003a) Indeed, at 
least thirteen residues of this sixty amino acid insert are disordered in the structure 
(Figure 1), providing tantalizing clues for an additional or novel surface on PXR (beyond 
the coactivator cleft) for protein-protein interactions, underscoring the relevance of 
mapping and characterizing these surfaces of full-length PXR that mediate protein 
interactions contributing to transactivation. 
 
Coregulators of PXR  
While PXR shares many characteristics with other members of the nuclear 
receptor superfamily, it also exhibits traits that are significantly unique. For example, 
though PXR is a ligand-activated transcription factor, it is distinctive from other nuclear 
receptors in that it responds to a large number of structurally diverse ligands. While some 
receptors are well-characterized (such as the estrogen receptor), PXR is less well 
understood, especially regarding the binding partners that help PXR stimulate or repress 
transcriptional activation of a target gene. Like other nuclear receptors, PXR binds to 
XREs (xenobiotic response elements) as a heterodimer with RXRα in the nucleus on the 
DNA of target genes. PXR has been shown to interact with the corepressor SMRT in the 
absence of agonist. (Johnson, D.R., et al. 2006) The corepressor prevents transcription of 
the target genes by deacetylating histones within their promoter regions. In the presence 
of agonist, the receptor-agonist complex can associate with coactivators (e.g. SRC-1) 
(Itoh, M., et al. 2006; Li, T., et al. 2007; Masuyama, H., et al. 2005) and allow large 
transcription complexes to form on target gene promoters. Either the coactivators or the 
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proteins they recruit have histone acetyl transferase activity, leading to chromatin 
decondensation and gene transcription. However, transcriptional activity is also 
influenced by promoter, nature of the agonist, and expression levels of coregulators in 
particular cell lines.  
The discovery of selective estrogen receptor modulators (SERMs), compounds 
with the ability to act as agonist or antagonist depending on the tissue context, has altered 
the view of nuclear receptor ligands. (McDonnell, D.P. 1999) More specifically, a 
compound may behave as an agonist in one tissue and an antagonist in another. Clearly a 
binary switch is insufficient to represent such intricacies as these tissue-specific 
interactions or the influence of differential cofactor expression levels. The diversity in 
ligand structure alone may add a level of complexity not shared by prototypical nuclear 
receptors.  
Recent data analyzing PXR protein interactions include directed yeast and 
mammalian two hybrid studies, as well as GST pull-down and coimmunoprecipitation 
assays (Bhalla, S., et al. 2004; Sugatani, J., et al. 2005; Synold, T.W., et al. 2001; 
Takeshita, A., et al. 2002). In a yeast two-hybrid experiment, Masuyama et al. confirmed 
that full length mouse PXR (mPXR) in the presence of some endocrine disrupting 
chemicals (nonylphenol or phthalic acid) interacts with steroid receptor coactivator-1 
(SRC-1) and receptor interacting protein 140 (RIP-140), but not suppressor for gal-1 
(SUG1). (Masuyama, H., et al. 2000) However, in the presence of progesterone, 
dexamethasone, or pregnenolone mPXR interacted with SRC-1 and RIP140, as well as 
SUG1. (Masuyama, H., et al. 2001) As discussed above, the cross-species specificity of 
PXR emphasizes the importance of performing these experiments with human PXR. 
 41
Studies of coregulator interactions with human PXR to date use an LBD-only construct 
and are summarized below. (Synold, T.W., et al. 2001; Takeshita, A., et al. 2002) In 2001, 
directed mammalian two-hybrid experiments were performed in CV-1 cells using human 
PXR LBD (hPXR LBD) in the presence of paclitaxel or docetaxel, demonstrating that 
hPXR LBD interacts with human SRC-1, mouse glucocorticoid receptor interacting 
protein 1 (GRIP1), human activator for thyroid hormone and retinoid receptors (ACTR), 
and human vitamin D receptor-interacting protein complex component (DRIP205, also 
called PBP and TRAP220). (Synold, T.W., et al. 2001) In this same study, hPXR LBD 
alone and in the presence of docetaxel interacted with the corepressor silencing mediator 
of retinoid and thyroid hormone action (SMRT), and to a lesser extent nuclear receptor 
corepressor (NCoR). (Synold, T.W., et al. 2001) However, because the N-terminal 
domain and DBD of nuclear receptors has been shown to modulate conformation of and 
interactions with the adjacent LBD (Hall, J.M., et al. 2002), it is critical to determine 
these interactions in the context of the full-length receptor, which this study enables. 
Additionally, a subsequent study has suggested that the effects of a xenobiotic on the 
PXR LBD-SMRT interaction are cell-type specific because the PXR LBD-SMRT 
interaction was increased by rifampicin or corticosterone treatment in HepG2 cells, while 
this effect did not occur in CV-1 cells. (Takeshita, A., et al. 2002) These findings suggest 
that regulation of PXR is indeed a complex, cell type-specific process. 
 
In order to better characterize PXR, M13 phage display system was used to 
identify peptides that PXR LBD binds in the presence and absence of two very different 
ligands (small SR12813, and large rifampicin). Additionally, full-length PXR was 
 42
generated and panned with M13 phage display. Three surfaces are present in the ligand 
binding domain (LBD) of PXR: i. the coactivator binding cleft, ii. the interface for 
heterodimerization with RXR, and iii. a novel PXR homodimerization interface. It is 
possible that full-length PXR exposes novel surfaces involved in tissue-specific protein-
protein interactions; this study identified a consensus sequence for peptides that bound to 
PXR LBD and created tools to help advance understanding of PXR’s interaction profile.  
 
Materials and Methods 
 
PXR LBD expression and purification  
PXR LBD was expressed and purified as previously determined in our laboratory. 
(Watkins, R.E., et al. 2001) Briefly, human PXR LBD (residues 130-434) was N-
terminally His-tagged and coexpressed with a fragment of SRC-1 (residues 623-710) in 
Escherichia coli BL-21 Gold cells (Stratagene). Cells were lysed by sonication, and the 
clarified cell lysate was purified using ProBond nickel-chelating resin (Invitrogen). The 
Ni-column fractions were analyzed using a Bradford assay only, and all fractions 
containing protein were loaded to an SP sepharose column as they eluted from the Ni-
column. Protein eluting from the SP column was diluted to prevent precipitation caused 
by high salt concentrations. The fractions containing PXR were concentrated to 5 mg/mL. 
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Full length PXR and RXR expression and purification 
Full-length PXR was subcloned from the pSG5 vector (generaous gift from G. 
Bruce Wisely at GlaxoSmithKline) into the pDW464, a BioBac baculovirus transfer 
vector (Duffy, S., et al. 1998) The BioBac technology fuses a 23 amino acid biotin 
acceptor peptide (BAP) to the preferred terminus of a protein (in this case the N-
terminus), and allows co-expression of the protein of interest and E.coli biotin 
holoenzyme synthetase (BirA) in Spodoptera frugiperda (Sf9) cells. BirA attaches a 
biotin moiety to a single lysine residue in the BAP sequence. The pDW464 transfer 
vector encoding full length human PXR and E.coli biotin holoenzyme synthetase (BirA) 
was recombined with baculovirus DNA in vivo using the Bac-to-Bac baculovirus 
expression system (Invitrogen). Cellfectin Reagent (Invitrogen) was used according to 
manufacturer’s instructions to transfect 9 x 105 Sf9 cells (in one well of 6-well plate) with 
the generated bacmid (1 μg). After transfection, the cells were incubated at 27°C for 3 
days. The virus-containing media was collected and 0.4 mL (estimated MOI = 0.25 
pfu/cell) was used to infect 8 x 106 cells in a 10 cm plate for 2 days. Sequential 
amplifications were performed in 10 cm plates with 8 x 106 cells. Virus-containing media 
was saved, and cells were scraped, lysed, and analyzed by sequential Western blot as 
described below to verify production of biotinylated PXR. The RXR recombinant 
baculovirus used was a gift from Julie Hall (Duke University). 
Sf9 cells were grown in suspension culture in Sf-900II Serum-free medium 
(SFM) at 27°C. 100 mL of cells at a density of 2.5 x 106 cells/mL were infected with 
either 1 mL of PXR baculovirus or 0.75 mL of RXR baculovirus then allowed to grow for 
48 hours. Centrifugation was used to harvest the cells, and cell pellets were snap-frozen 
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in a dry-ice/ethanol bath then stored at -20°C. Cells pellets were thawed on ice, 
resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM β-mercaptoethanol, 100 
mM KCl, 1% NP-40, 1:200 protease inhibitor cocktail set III, 50 mM NaF, 50 mM β-
glycerophosphate) and rocked at 4°C for 1 hour to allow lysis. Lysate was then cleared by 
centrifugation at 48,000 x g for 30 min at 4°C. Affinity purification was done according 
to the commercial protocol using streptavidin mutein matrix (Roche); however, a 
different elution buffer was used (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 2 mM EDTA, 
4 mM DTT, 10% glycerol, 1 mM CHAPS, 5 mM biotin). 
 
Western Blot analysis  
Cell lysates, purification washes, and fractions from above expression and 
purification were separated on a 10% SDS-PAGE gel, then transferred to nitrocellulose 
(Amersham Biosciences, Inc.). PXR protein was detected using the PXR N-16 antibody 
and horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz 
Biotechnology). Biotinylated proteins were detected using the streptavidin-horseradish 
peroxidase conjugate (Amersham Biosciences, Inc.). Chemiluminescence was used for 
visualization (Amersham Biosciences, Inc.). 
 
Phage Display  
Phage display has been successfully used for many different nuclear receptors 
(Chang, C., et al. 1999); and when determining the adaptability of PXR to this protocol, 
ERβ (estrogen receptor beta) was used simultaneously as a positive control. For panning, 
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10 pmol of pure PXR (LBD or full length) per well was diluted in 100μL of NaHCO3 
(pH 8.5) containing the appropriate ligand (1 μM of either SR12813, rifampicin, or 17-β 
estradiol) and incubated in a 96-well tissue culture plate (Corning) at 4ºC overnight. The 
wells were then blocked with MPBS [2% milk in PBS, 137mM NaCl, 2.7 mM KCl, 4.3 
mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.4)] containing appropriate ligand at room 
temperature for one hour, and the phage library was pre-cleared by mixing 5 x 109 phage 
per well with 100 μL MPBS (with ligand, if appropriate) on ice for one hour. The 
blocking/pre-clearing step ensures that the peptides that non-specifically bind protein 
were removed from the library. Subsequently, the wells coated with target protein were 
washed five times with 300 μL PBST (PBS plus 0.1% Tween 20); then the pre-cleared 
phage libraries were added to the wells. Phage were incubated with the target protein for 
2 hours at room temperature, then wells were washed ten times with 300 μL PBST to 
remove phage that had not bound to the immobilized protein. The phage that bound were 
eluted from the wells with 100 μL of 0.1 M HCl for 10 minutes, excess acid was 
neutralized at the end of elution with 50 μL of 1 M Tris-HCl (pH 7.4). The eluted phage 
(minus 15 μL reserved to determine elution titer) were inoculated into 5 mL of log-phase 
DH5αF’ for 20 minutes without shaking at 37°C, then amplified for 5 hours in a shaking 
incubator at 37°C. The supernatant of the DH5αF’ culture containing the amplified phage 
was harvested and stored at 4ºC. To determine titers, serial 10x dilutions were made of 
eluted phage and amplified phage in PBST; the dilutions (10-3, 10-4, 10-5 for elution titer 
and 10-7, 10-8, 10-9 for amplification titer) were plated with X-gal, IPTG, and fresh 
DH5αF’. After overnight incubation, the blue colonies were counted and used to 
determine the pfu (plaque forming units) for each elution and amplification. Increases in 
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elution titer are indicative of selection for phage expressing peptides that specifically bind 
to the target protein. In the next pan, 5 × 109 amplified phage from the previous pan was 
used in place of the library, and the steps were repeated three more times. Enzyme-linked 
immunosorbent assay (ELISA) detecting the M13 coat protein (described below) was 
used to confirm enrichment of phage that bound to PXR LBD. Peptide inserts were 
amplified with PCR and subcloned into the pM3.1 vector for mammalian two-hybrid 
testing. Twenty-four constructs were randomly selected from each library-ligand 
combination and sequenced. The sequencing results were individually verified and 
translated. 
 
Enzym-linked immunosorbent assay   
For the ELISA, protein was immobilized onto a 96-well tissue culture plate 
(Corning) using the same procedure used for panning. Unlike panning, however, for each 
protein well a corresponding well was coated overnight with only milk to be used for the 
milk control. Just as described above for panning procedure, all wells were blocked with 
MPBS. A volume of supernatant corresponding to 5 x 109 phage was blocked with 
MPBST (PBS plus 2% milk and 0.1% Tween 20) for 1 hour on ice. The wells were then 
rinsed five times with 300 μL PBST, and the phage/MPBST solution was incubated with 
the target protein (or milk for the control) in the wells for 1 hour at room temperature. 
Wells were washed five times with 300 μL PBST to remove non-binding phage; but, 
instead of eluting, an ELISA was performed. Horseradish peroxidase-conjugated anti-
M13 antibody (Pharmacia) was diluted 1:5000 in PBST, then 100 μL of the diluted 
conjugate was added to each well and incubated at room temperature for 1 hour. The 
 47
wells were washed ten times with 300 μL PBST, then 100 μL of ABTS solution (2’-2’-
azino-bis-ethylbenzthiazoline-6-sulfonic acid solution with freshly added 0.05% H2O2) 
was added to each well. After 10 minutes, the absorbance at 405 nm was read using a 
microtiter plate reader. Comparison of each phage pool incubated with PXR LBD to the 
matching phage + milk control demonstrated the isolated phage specifically interacted 
with PXR LBD. 
 
Cell culture and transient transfections 
HepG2 and HeLa cells were cultured as previously described in the literature 
using minimum essential medium (GIBCO, Invitrogen) supplemented with 10% fetal 
bovine serum (FBS, HyClone), 0.1 mM nonessential amino acids, and 1 mM sodium 
pyruvate (GIBCO, Invitrogen) and were maintained in a humidified 37°C incubator 5% 
CO2. (Chang, C., et al. 1999) 24 hours before transfection, the cells were seeded into 96-
well or 24-well plates.  For mammalian two-hybrid, a modification of the CloneTech 
protocols was used. (Chang, C., et al. 1999) First, the phage peptides were amplified by 
PCR using primers to the identical vector sequences flanking the diverse peptides. Then 
these sequences containing the diverse peptides were ligated into the mammalian two-
hybrid pM GAL4-DNA binding domain cloning vector (CloneTech). Initially, five 
colonies were chosen at random for each of the eight samples (peptides from the LxxLL 
library that bound PXR alone, PXR and SR12813, PXR and rifampicin, or PXR and 17β-
estradiol and peptides from the CoRNR library that bound each of these species); the 
DNA was amplified in and isolated from DH5α. HepG2 cells were transiently transfected 
using Lipofectin (Invitrogen) per the manufacturer’s instructions in a 96-well plate with a 
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single pM (Gal4DBD) vector, the VP16 vector containing full length PXR, the 
5×Gal4Luc3 plasmid, and the CMVβGal plasmid. The cells were incubated with the 
DNA-Lipofectin mix for 5 hours; then the solution was removed to stop the transfection 
and new medium was added. After 24 hours, media was exchanged for fresh media 
containing ligands (1 μM SR12813, 10 μM rifampicin, and 100 μM 17β-estradiol) were 
added. After 16 hours incubation at 37ºC, luciferase and β- galactosidase activities were 
measured. Normalization of luciferase induction with β-galactosidase activity expressed 
from a constitutive cotransfected control plasmid represented specific interaction between 
peptide and PXR. 
For activation of transcription by SRC-1, GRIP-1 or PGC-1α, Lipofectin was 
used to transfect the following plasmid amounts per triplicate: 50 ng of either 
pcDNA3.1nvDEST or pcDNA3.1_PXR, 1500 ng of either pGL3_XREMluc+ or pDR-4, 
100 ng CMVβGal, and increasing amounts of either pSG5-SRC-1, pSG5-HA-GRIP-1, or 
pcDNA-M-H-fl-PGC1a plasmid. The number of moles of promoter was held constant by 
using appropriate concentrations of empty pSG5 or pcDNA3.1 vectors; finally, total DNA 
input was balanced using the empty plasmid PBSII. The cells transfected, treated, and 
analyzed as above. 
 
Generation of T7 libraries  
Human small intestine poly(A) RNA was purchased from Ambion, Inc. T7 Select 
protocols and reagents, including Orient Express cDNA cloning system, (Novagen) were 
used according to the manufacturer’s instructions to generate 10-3 and 1-1 T7 libraries 
from small intestine mRNA (Ambion).  
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Results and Discussion 
 
Activation of PXR Transcription by GRIP-1 and PGC-1α 
To determine whether PGC-1α and GRIP-1 were able to potentiate PXR activity 
on the DR-4 and XREM-CYP3A4-luciferase (Watkins, R.E., et al. 2001) promoter 
reporter constructs, HepG2 and HeLa cells were transiently transfected with fixed 
amounts of PXR and increasing amounts of coactivator plasmid in the presence and 
absence of rifampicin. Both GRIP-1 and PGC-1α activated PXR transcription on the DR-
4 and XREM promoters in HepG2 and HeLa cells. Activation profiles on the XREM-
CYP3A4-luciferase promoter from HepG2 cells are presented in Figures 2.1, 2.2, and 
2.3. (HeLa and DR-4 data not presented for redundancy.) The same experiment was 
performed using SRC-1 for comparison. GRIP-1 and PGC-1α expression resulted in 
nearly 2-fold greater transactivation than did SRC-1. Additionally, Figure 2.4 shows a 
dose-response of PXR transfected together with a constant (500 ng) amount of GRIP-1. 
Coexpression of PXR with GRIP-1 or SRC-1 resulted in a small amount of rifampicin-
independent transcription that was substantially increased by addition of rifampicin. 
However, coexpression of PXR and PGC-1α primarily seemed to affect the activity of 
PXR in the absence of ligand, though addition of rifampicin did enhance the 
transcriptional activity. This data could be explained by PGC-1α interacting with the 
DBD of PXR, as has been observed for FXR (Zhang, Y., et al. 2004).  
PXR has been shown to bind to PGC-1α and to compete with HNF-4 for 
interaction with PGC-1α, thereby interfering with HNF-4 activity on CYP7A1 and 
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CYP8B1 (Bhalla, S., et al. 2004). Additionally, PXR demonstrated an ability to interact 
with GRIP-1 in a GST pull-down assay (Sugatani, J., et al. 2005). The results presented 
here demonstrate that GRIP-1 and PGC-1α are quite effective at potentiating PXR 
transcription on the DR-4 promoter and the XREM-CYP3A4-luciferase promoter in 
HepG2 and HeLa cells.  
 
Production of full length PXR and RXR 
Much of the information currently available about PXR-coregulator interactions 
was determined using LBD constructs. Though some surfaces presented by full-length 
PXR may overlap with those presented by the LBD alone, it is critical to use full-length 
receptor for studying the PXR cellular signaling pathway. Until now, this effort has been 
hindered by the inability to prepare sufficient quantities of pure PXR. These difficulties 
were overcome by utilizing the BioBac baculovirus expression system in Spodoptera 
frugiperda (Sf9) cells. (Duffy, S., et al. 1998) The BioBac technology fuses a ~23 amino 
acid biotin acceptor peptide (BAP) to the preferred terminus of a protein (the N-terminus 
of PXR), allowing the co-expressed E.coli biotin holoenzyme synthetase (BirA) to attach 
a biotin moiety to a single lysine residue in the BAP sequence. The RXR baculovirus 
used was also generated using the BioBac technology. Full length PXR and RXR were 
purified separately using a single step of affinity chromatography with streptavidin 
mutein matrix (Roche Applied Science). Sequential Western blot analysis demonstrated 
that the band migrating at approximately 52 KDa was biotinylated PXR. Each 100 mL of 
Sf9 culture yielded approximately 300μg of pure RXR and 100 μg of pure PXR. 
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Panning PXR LBD and full length PXR.  
To determine consensus peptide motifs that interact with PXR LBD, the LxxLL 
and CoRNR (CoRepressor of Nuclear Receptors) libraries have been screened against 
wild-type PXR LBD alone or in the presence of 1 μM agonist (SR12813, rifampicin, or 
17β-estradiol). The peptide sequences from interacting phage were amplified using PCR, 
then subcloned into a mammalian two-hybrid vector for testing interaction with full 
length PXR. Additionally, full-length PXR has been used as a target for screening the 
LxxLL, C-S, and X6LX6 libraries. For full-length studies, three rounds of panning were 
completed; however, due to time constraints cloning and mammalian two-hybrid 
verification of interaction were not completed. 
 
PXR LBD panning results  
The LxxLL library is based on the known coactivator motif, but contains 
randomized flanking sequences of seven amino acids (x7-L-x-x-L-L-x7). (Chang, C., et al. 
1999) Similarly constructed, the CoRNR library is based on the known corepressor motif 
L-x-x-H/I-I-x-x-x-I/L. (Huang, H.J., et al. 2002) Figure 2.5 contains elution titer data for 
pans of PXR LBD in the presence of rifampicin with both libraries; these data are 
representative of data for all pans. As Figure 2.5 indicates, sequential panning (using the 
phage from the previous pan) leads to an increase of elution titer indicating enrichment of 
phage displaying peptides that bind to the PXR LBD-rifampicin complex. (In these 
experiments, pans with ERβ were performed in parallel as a positive control; results not 
shown.) Elution titer is only a rough estimate of target phage interaction, so the more 
sensitive ELISA was used to verify that the panning enriched for those phage bearing 
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peptide sequences that bind to PXR LBD. The ELISA results indicate that the phage 
bound to PXR LBD with an increase in binding phage seen in the second pan for the 
CoRNR library (Figure 2.6). The signal for the LxxLL library was already high in the 
first pan, indicating a rapid enrichment for this library (Figure 2.6). The milk control did 
not show enrichment, confirming that this binding was specific for PXR LBD-ligand 
(data not shown). Decrease in interaction seen by ELISA in later pans with LxxLL could 
be explained by loss of weak binders in later pans or by some phage species amplifying 
much faster than the rest. For initial mammalian two-hybrid studies, phage from the 
second pan for both libraries in the presence of each PXR LBD/ligand combination were 
chosen to try to ensure the greatest diversity of peptide sequences. 
To determine whether the peptides found to interact in the phage display assay 
also interact in a cell-based system, mammalian two-hybrid experiments were conducted. 
Each mammalian two-hybrid screen was performed at least twice with triplicate samples 
in each experiment. Interaction patterns were classified as one of five categories:  
A) peptide construct was not recruited by full-length PXR in the absence 
or presence of agonist  
B) peptide construct was not recruited by full-length PXR in the absence 
of agonist, but was recruited with the addition of agonist  
C) peptide construct was recruited equally well in the absence and 
presence of agonist  
D) peptide construct was recruited in the absence of agonist, but presence 
of agonist further enhanced the interaction  
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E) peptide construct was recruited in the absence of agonist, and addition 
of agonist diminished the interaction.  
Results representative of each class of peptide are presented in Figure 2.7. All results are 
summarized and classified in Tables 2.1-6. Initially, 96-well plates were used for the 
mammalian two-hybrid assays; subsequently, 24-well plates were used because it was 
determined that the 24-well plate format provided less experimental variation.  
Sequences that interacted with a class D pattern (the most abundant) were 
examined for conserved motifs and were compared to known NR box classes I-IV. 
Figure 2.8. A proline in the -2 position was highly conserved among peptides that 
interact with PXR LBD; and many of these sequences also contained a hydrophobic 
residue at the -1 position, making them members of class II NR boxes. Know coactivators 
with class II NR boxes include TRAP220 and RIP140 (Chang, C., et al. 1999). The motif 
discovered for PXR extends beyond the class II NR box: preferring a polar residue in the 
-3 position. 
One unexpected result was that CoRNR peptides bound to PXR LBD in complex 
with agonist. Sequence analysis demonstrated that while these peptides had the conserved 
corepressor motif discussed, some also had LxxLL-like (LxxML, IxxLL, etc.) motifs. 
(Figure 2.9) All had at least one of the three preferred upstream residues, and most of the 
peptides had all three. One CoRNR construct demonstrated interaction pattern E 
(pM_R_C3). Two other constructs (pM_alone_L18 and pM_alone_L19) also 
demonstrated interaction pattern E, although pM_alone_L19 interaction was only 
consistent in the presence of rifampicin. The pM_alone_L18 construct (and 
pM_alone_L19 in the presence of SR12813) exhibited interaction profile C in other trials. 
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The sequences of the three peptides that interacted with pattern E are shown in Figure 
2.10. The pM_R_C3 sequence only has the -3 polar residue. However this is also true of 
the pM_alone_C1 sequence (identical sequence to pM_S_C15 and pM_R_C1) which 
interacts with PXR in a different profile in the mammalian two-hybrid system. 
Of the peptides that followed the class A profile of interaction, 40% did not 
sequence. Poor sample quality would explain the lack of interaction in the mammalian 
two-hybrid assay for these constructs. For the other 60%, however, other options must be 
considered. These constructs are listed with their sequences in Figure 2.11. Two of them 
were identical to sequences from other phage that did interact in the mammalian two-
hybrid system. Because the sequences discussed in this section were selected using PXR 
LBD, it may be that some of the profile A sequences do not interact with full length PXR 
which was used in the mammalian two-hybrid assay, but will interact when tested with a 
PXR LBD construct. Two of the sequences do not contain any of the upstream three 
residues of the described interaction motif, but several of the sequences contain one or 
more of those characteristics. Clearly the next step in this process is to test all of the 
peptides in the mammalian two-hybrid system using a PXR LBD pVP16 construct. 
 
Full-length PXR panning results  
Full-length PXR alone and in the presence of 1μM SR12813 or rifampicin was 
used to pan the LxxLL, C-S, and X6LX6 libraries. Three rounds of panning were 
completed, and ELISA results are depicted in Figure 2.12. Full-length PXR behaved 
quite differently than did PXR LBD as evidenced by the LxxLL library not beginning to 
enrich until the third round of panning. At least one more pan of the X6LX6 library and 
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two more pans of the LxxLL library should be performed, followed by cloning and 
mammalian two-hybrid verification of interaction with full-length PXR and PXR LBD 
pVP16 constructs.  
 
Generation of T7 libraries 
With the example of SERMs variable regulation of the estrogen receptor and the 
discrepancy between PXR results in CV-1 and HepG2 cells, it is increasingly necessary 
to think of PXR regulation in a tissue-specific context. For this reason, a high-throughput 
screen of tissue-specific T7 libraries should be done on full-length PXR. The T7 cDNA 
expression system is novel because its libraries are tissue specific and, because the phage 
lyse, the protein fragment size is not as limited as it is in the M13 system; indeed the T7 
system has up to a 1200 amino acid capacity. Libraries existing in the lab include those 
developed from liver and colon cell lines as well as brain (where PXR is suggested to 
play a role in mood). PXR is highly expressed in liver, colon, and small intestine; since 
no library for small intestine had been generated yet, 1-1 (0.1-1 copy target per phage) 
and 10-3 (5-15 copies target per phage) small intestine libraries were successfully 
generated from purchased human poly(A) RNA, although time did not permit screening.  
 
Future Directions 
 
The preliminary results presented here indicate that full length PXR can be 
produced and that PXR is amenable to the phage display and mammalian two-hybrid 
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protocols developed in the McDonnell lab. To complete the studies, the M13 peptides 
found by panning PXR LBD should be tested in mammalian two-hybrid with the 
VP16_PXR LBD constructs that have been generated. Additionally, the M13 phage that 
were found by panning full length PXR should be carried forward through amplification, 
sequencing, and mammalian two-hybrid (analyzing with ligand panned with, and other 
ligands) as well. It will be interesting to compare and contrast those sequences to the ones 
found with LBD.  These data will sample the full spectrum of interacting peptide 
sequences for PXR in the full-length receptor context and determine whether different 
sequences show specificity for different classes of PXR ligands. Another necessary step 
is determining the specificity of these peptides by cross-testing them with other nuclear 
receptors to ask whether their interactions are unique to PXR. Based on sequence 
similarity, I expect that at the very least many of the peptides found in the M13 PXR 
LBD screens may also bind to PPARs (unpublished results from Niharika Mettu). If one 
or more peptides are determined to be specific for PXR only, however, these can be 
utilized to make vital tools for examining PXR biology as has previously been done for 
ERR. (Gaillard, S., et al. 2006; Gaillard, S., et al. 2007) 
The peptides from this study could also provide the missing link to allow 
crystallization of full-length PXR by binding to and stabilizing uncharacterized surfaces 
of the receptor, much like SRC-1 and other coactivator fragments stabilize AF2 for 
crystallization of ligand binding domains. The completion of T7 studies, panning the 
PXR-RXR heterodimer with tissue-specific libraries could greatly illuminate the 
understanding of which proteins bind to and regulate PXR function. 
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In conclusion, the studies initiated here lay the foundation for answering several 
fundamental questions regarding the regulation of xenobiotic metabolism, including those 
regarding (a) the surfaces full-length PXR presents in the presence of different ligands, 
(b) which coregulators mediate the transcriptional activity of PXR in context of the full-
length receptor, (c) whether or not ligands produce distinct protein-PXR interactions in 
different tissues, and (d) whether coregulators show specificity for different classes of 
PXR ligands. The completion of these and future experiments will delineate in detail the 
PXR signaling pathway for xenobiotic metabolism. This knowledge could provide 
valuable insights into controlling dangerous drug-drug interactions and tailoring dosing 
regimen to individuals. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_alone_L1 MGSRGPSDFPILWNLLTTSVSGDSSS A n.d. 
pM_alone_L2 MGSRLGESHPLLMQLLTENVGTHSSS D n.d. 
pM_alone_L3 MGSRLSALYPELSRLLSVDVHALSSS a n.d. 
pM_alone_L4 MGSSTVDTYPLLRALLADSPSIGSSS b n.d. 
pM_alone_L5 MGSRTVLDGMSLERLLIVGGLSVSSS n.d. n.d. 
pM_alone_L13 MGSRLESLYPELYQLLSPGKLSLSSS D D 
pM_alone_L14 MGSRLLEAHPLLTGLLGASSLELSSS C C 
pM_alone_L15 MGSRVVDSYPVLTELLRRDEAELSSS D D 
pM_alone_L16 MGSRGDLKCTMLASLLTDCSVASSSS A A 
pM_alone_L17 no seq A A 
pM_alone_L18 MGSRLMLENPLLAQLLGAELPSQSSS C, E, C C, E 
pM_alone_L19 MGSRPWFDNPLLFKLLSEESHESSSS C, E, C E, E 
pM_alone_L20 MGSRLGESHPLLMQLLTENVGTHSSS D D 
pM_alone_L21 MGSRGPDGYPTLRELLGYPSTRVSSS d d 
pM_alone_L22 no seq A A 
pM_alone_L23 MGSSLSDSHPVLTALLAECMGDCSSS D D 
pM_alone_L24 MGSSISSDYPLLHALLQDDYSSTSSS D *C 
 
Table 2.1. LxxLL peptide data from pan 2 of PXR LBD in the absence of ligand. The 
LxxLL motif is underlined. Interaction classes are described in the text. Lower case 
letters for class of interaction indicate instances where the interaction seen was 
statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_alone_C1 MGSSDRLLRYYLSENIKQLIPGIEYNGSSS D D 
pM_alone_C2 MGSSVSYYGANLNPIIRGYLTGGMWSMSSS A A 
pM_alone_C3 MGSSWSNQAVILHPHIAGLLMPQETFTSSS D D 
pM_alone_C4 MGSSHPILRDMLTNNIDPQIRETEGPLSSS d n.d. 
pM_alone_C5 MGSSPRPVIEELYPNIHALLMSTREGASSS n.d. n.d. 
pM_alone_C13 MGSSHPILRDMLTNNIDPQIRETEGPLSSS A n.d. 
pM_alone_C14 no seq C n.d. 
pM_alone_C15 MGSSTEYDLCTLYPNIMQALQNEPCHQSSS *C D 
pM_alone_C16 MGSSHPILRDMLTNNIDPQIRETEGPLSSS   D D 
pM_alone_C17 no seq A A 
pM_alone_C18 MGSSTEYDLCTLYPNIMQALQNEPCHQSSS D *A 
pM_alone_C19 no seq A, D C 
pM_alone_C20 MGSSHPILRDMLTNNIDPQIRETEGPLSSS C C 
pM_alone_C21 MGSSPPILRDMLTNNIDPQIRETEGPLSSS   D D 
pM_alone_C22 no seq A, C C 
pM_alone_C23 no seq D, A A 
pM_alone_C24 MGSSNTRDLSSLYPLIHGLLIQNTEGVSSS D D, *C 
 
Table 2.2. CoRNR peptide data from pan 2 of PXR LBD in the absence of ligand. 
The CoRNR motif is underlined. Interaction classes are described in the text. Lower case 
letters for class of interaction indicate instances where the interaction seen was 
statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_SR_L1 MGSSNGSDYQILRQLLASEQLLLSSS A n.d. 
pM_SR_L2 MGSSISYEHPLLTGLLLEQRHVDSSS A n.d. 
pM_SR_L3 MGSSLESLYPELYQLLSPGKLSLSSS A n.d. 
pM_SR_L4 MGSRGVDAYPLLSALLSAENGVESSS c n.d. 
pM_SR_L5 MGSSMISLNPVLMGLLQERLDWSSSS D D 
pM_SR_L13 no seq D n.d. 
pM_SR_L14 MGSSTWMAYPTLSELLQAPVEGVSSS C n.d. 
pM_SR_L15 no seq A n.d. 
pM_SR_L16 MGSRVELAFPLLRELLSQPLWVDSSS *C n.d. 
pM_SR_L17 MGSSTIDSHPMLFNLLSKSESFVSSS D n.d. 
pM_SR_L18 MGSSNAVLTPILQSLLLGADVKQSSS *C n.d. 
pM_SR_L19 MGSSVLSDYPLLYQLLDYGLDRGSSS *C n.d. 
pM_SR_L20 MGSRIIRDNPELCVLLDCSSERISSS A, d d 
pM_SR_L21 MGSSVFLENRLLYGLLTSQTEPSSSS C, D D 
pM_SR_L22 MGSSSWVETPMLYSLLRDDKTIWSSS *C n.d. 
pM_SR_L23 MGSSTQMENPILEALLLGKAIQMSSS D n.d. 
pM_SR_L24 MGSSIADDAPLLRSLLESGLTVSSSS D, e n.d. 
 
Table 2.3. LxxLL peptide data from pan 2 of PXR LBD in the presence of 1 μM 
SR12813. The LxxLL motif is underlined. Interaction classes are described in the text. 
Lower case letters for class of interaction indicate instances where the interaction seen 
was statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_SR_C1 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D n.d. 
pM_SR_C2 MGSSITHSHPVLTGLILGDLPVDRTLLSSS c n.d. 
pM_SR_C3 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D n.d. 
pM_SR_C4 MGSSPISHQYPLMLNILGHIDTHTTPTSSS b n.d. 
pM_SR_C5 MGSSNENSAVQLHPIIRHMLLGSPETGSSS n.d. n.d. 
pM_SR_C13 no seq D n.d. 
pM_SR_C14 MGSSHPILRDMLTNNIDPQIRETEGPLSSS *C n.d. 
pM_SR_C15 MGSSDRLLRYYLSENIKQLIPGIEYNGSSS *C n.d. 
pM_SR_C16 no seq D n.d. 
pM_SR_C17 MGSSHPILRDMLTNNIDPQIRETEGPLSSS *C n.d. 
pM_SR_C18 MGSSITHSHPVLTGLILGDLPVDRTLLSSS *C n.d. 
pM_SR_C19 MGSSYKQWNHQLSTHIKNPIQPTVTKHSSS A n.d. 
pM_SR_C20 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D n.d. 
pM_SR_C21 MGSSPRPVIEELYPNIHALLMSTREGASSS B n.d. 
pM_SR_C22 MGSSYSDTAHTLTPIIRSMLLPSFPNTSSS A n.d. 
pM_SR_C23 MGSSHPILRDMLTNNIDPQIRETEGPLSSS *C n.d. 
pM_SR_C24 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D n.d. 
 
Table 2.4. CoRNR peptide data from pan 2 of PXR LBD in the presence of 1 μM 
SR12813. The CoRNR motif is underlined. Interaction classes are described in the text. 
Lower case letters for class of interaction indicate instances where the interaction seen 
was statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_R_L1 MGSSSLHETPLLLRLLSSEPASVSSS n.d. B 
pM_R_L2 MGSSTSLDFPVLSSLLNWNSEEVSSS n.d. b 
pM_R_L3 MGSRGAEGYPLLRQLLAHTQPRLSSS  n.d. b 
pM_R_L4 MGSRLESLYPELYQLLSPGKLSLSSS n.d. b 
pM_R_L5 MGSSNFGPYPILTELLSSGGSLVSSS n.d. n.d. 
pM_R_L13 MGSRMVTEYPILSELLQGPPTFVSSS n.d. D 
pM_R_L14 MGSRTLDTTPLLLQLLQHPGSAESSS n.d. D 
pM_R_L15 no seq A A 
pM_R_L16 MGSSSWVETPMLYSLLRDDKTIWSSS D D 
pM_R_L17 no seq A A 
pM_R_L18 MGSRAFPDSPILRALLSQSYGSPSSS D D 
pM_R_L19 MGSRLESLYPELYQLLSPGKLSLSSS D D 
pM_R_L20 no seq A, A D, A 
pM_R_L21 MGSSVTSPTPILLHLLGDVSEHVSSS D D 
pM_R_L22 MGSSQALDYPILRELLGAPGLSLSSS D D 
pM_R_L23 MGSSDLTRYPVLWELLTQGSGAESSS D D 
pM_R_L24 MGSSIADDAPLLRSLLESGLTVSSSS   B B, A 
 
Table 2.5. LxxLL peptide data from pan 2 of PXR LBD in the presence of 1 μM 
rifampicin. The LxxLL motif is underlined. Interaction classes are described in the text. 
Lower case letters for class of interaction indicate instances where the interaction seen 
was statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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Plasmid Name Sequence 
Class of 
Interaction 
with 
SR12813 
Class of 
Interaction 
with 
Rifampicin 
pM_R_C1 MGSSDRLLRYYLSENIKQLIPGIEYNGSSS  n.d. b 
pM_R_C2 MGSSHPILRDMLTNNIDPQIRETEGPLSSS n.d. D 
pM_R_C3 MGSSVWVVNTDLDALIRSELLKGRGEKSSS E E 
pM_R_C4 MGSSHPILRDMLTNNIDPQIRETEGPLSSS n.d. D 
pM_R_C5 MGSSVLPGPLALYPNIMEWLRPVPNEESSS n.d. n.d. 
pM_R_C13 MGSSHPILRDMLTNNIDPQIRETEGPLSSS n.d. D 
pM_R_C14 MGSSPRPVIEELYPNIHALLMSTREGASSS  n.d. B 
pM_R_C15 MGSSTDVWSTYLSNLIRAQLNANPSQTSSS  A A 
pM_R_C16 MGSSHPILRDMLTNNIDPQIRETEGPLS A A 
pM_R_C17 no seq c c 
pM_R_C18 MGSSHPILRDMLTNNIDPQIRETEGPLSSS  D D 
pM_R_C19 no seq D D 
pM_R_C20 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D D 
pM_R_C21 MGSSHPILRDMLTNNIDPQIRETEGPLSSS D D 
pM_R_C22 no seq A A 
pM_R_C23 MGSSNQTARLDLHPLIRSLLGASEGPQSSS D D 
pM_R_C24 MGSSSSMSQQQLYPIIWSLISDSAMPTSSS  B B 
 
Table 2.6. CoRNR peptide data from pan 2 of PXR LBD in the presence of 1 μM 
rifampicin. The CoRNR motif is underlined. Interaction classes are described in the text. 
Lower case letters for class of interaction indicate instances where the interaction seen 
was statistically significant over level of pM_construct interaction with empty pVP16, 
however the actual luciferase activity levels were quite low, on the order of those pM 
constructs that did not interact. Multiple letters indicate peptides that had different 
responses between replicate trials. Asterisks indicate data where the error bars are quite 
large; n.d., not determined; no seq indicates peptides for which the sequencing reaction 
did not produce quality data. 
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PXR Transcription on XREM_CYP3A4_luc Enhanced by SRC-1 in HepG2 cells
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Figure 2.1. Transcriptional activation of PXR in the presence of SRC-1. SRC-1 
enhances PXR transcription of a reporter construct containing the XREM of the CYP3A4 
gene in HepG2 cells. HepG2 cells were transfected with PXR, the XREM_CYP3A4 
reporter construct, and either empty pSG5 or increasing concentrations of pSG5_SRC-1 
construct as indicated. Transfected cells were treated with DMSO or 10 μM rifampicin 
for 16 hours prior to lysis and analysis of luciferase expression. 
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PXR Transcription on XREM_CYP3A4_luc Enahnced by GRIP-1 in HepG2 cells
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Figure 2.2. Transcriptional activation of PXR in the presence of GRIP-1. GRIP-1 
enhances PXR transcription of a reporter construct containing the XREM of the CYP3A4 
gene in HepG2 cells. HepG2 cells were transfected with PXR, the XREM_CYP3A4 
reporter construct, and either empty pSG5 or increasing concentrations of pSG5_GRIP-1 
construct as indicated. Transfected cells were treated with DMSO or 10 μM rifampicin 
for 16 hours prior to lysis and analysis of luciferase expression. 
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PXR Transcription on XREM_CYP3A4_luc Enahnced by PGC-1α  in HepG2 cells
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Figure 2.3. Transcriptional activation of PXR in the presence of PGC-1α. PGC-1α 
also enhances PXR transcription of a reporter construct containing the XREM of the 
CYP3A4 gene in HepG2 cells. HepG2 cells were transfected with PXR, the 
XREM_CYP3A4 reporter construct, and either empty pcDNA3.1 or increasing 
concentrations of pcDNA3.1_PGC-1α construct as indicated. Transfected cells were 
treated with DMSO or 10 μM rifampicin for 16 hours prior to lysis and analysis of 
luciferase expression. 
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Dose-Response of PXR in the presence of 500ng GRIP-1 on XREM (HepG2)
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Figure 2.4. Dose-response of PXR in the presence of 500 ng GRIP-1. HepG2 cells 
were transfected with the XREM_CYP3A4 reporter construct, 500 ng of pSG5_GRIP-1, 
and increasing concentrations of pcDNA3.1_PXR construct as indicated. Transfected 
cells were treated with DMSO or 10 μM rifampicin for 16 hours prior to lysis and 
analysis of luciferase expression. 
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Binding of Phage from Two Different Libraries in 
Screens of PXR LBD bound to Rifampicin
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Figure 2.5. Elution titers for M13 pans of PXR LBD. Elution titers for phage bound to 
PXR LBD in the presence of 1 μM rifampicin increased over the course of panning both 
the LxxLL and CoRNR libraries.  
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ELISA Results for Phage from LxxLL and CoRNR Libraries that Bound to 
PXR LBD in the Presence and Absence of Agonists
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Figure 2.6.  ELISA assay results from M13 pans of PXR LBD in the presence and 
absence of ligand. PXR LBD was immobilized on a 96 well plate and incubated with 
phage isolated from sequential panning prior to washing and immunodetection. ELISA 
assay results for phage from each pan of the CoRNR and LxxLL libraries confirmed that 
the libraries enriched for PXR LBD binders over the course of panning. 
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Five Different Classes of Interaction between M13 Peptides and Full-Length PXR 
in Mammalian Two-Hybrid System
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Figure 2.7. Data representative of each interaction profile. HepG2 cells were 
transfected with pM_peptide constructs, empty VP16 or pVP16_PXR (full length), the 
5xGal4Luc3 reporter construct, and the CMVβGal plasmid. Transfected cells were 
treated with DMSO or 10 μM rifampicin for 16 hours prior to lysis and analysis of 
luciferase expression. The interaction profiles of peptide constructs and the full-length 
PXR VP16 construct were categorized as follows: A) peptide construct was not recruited 
by full-length PXR in the absence or presence of agonist; B) peptide construct was not 
recruited by full-length PXR in the absence of agonist, but was recruited with the 
addition of agonist; C) peptide construct was recruited equally well in the absence and 
presence of agonist; D) peptide construct was recruited in the absence of agonist, but 
presence of agonist further enhanced the interaction; E) peptide construct was recruited in 
the absence of agonist, and addition of agonist diminished the interaction. Data 
representative of each class are presented.  
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Figure 2.8. LxxLL peptides sequences that interacted with PXR. Conserved motifs 
were found in LxxLL sequences that interacted with PXR and that interaction was further 
enhanced by ligand. (Two sequences are omitted because they are identical to others in 
the figure.) All but one has a proline in the -2 position, and all but one has a hydrophobic 
residue in the -1 position. The known NR boxes (class I-IV) are depicted for comparison. 
The predominant profile found in these sequences follows class II pattern. In addition, 
PXR LBD seems to select a polar residue in the -3 position. 
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MGSSDRLLRYYLSENIKQLIPGIEYNGSSS
MGSSWSNQAVILHPHIAGLLMPQETFTSSS
MGSSHPILRDMLTNNIDPQIRETEGPLSSS
MGSSNTRDLSSLYPLIHGLLIQNTEGVSSS
MGSSITHSHPVLTGLILGDLPVDRTLLSSS
MGSSPISHQYPLMLNILGHIDTHTTPTSSS
MGSSPRPVIEELYPNIHALLMSTREGASSS
MGSSNQTARLDLHPLIRSLLGASEGPQSSS
MGSSSSMSQQQLYPIIWSLISDSAMPTSSS 
 
Figure 2.9. CoRNR peptide sequences that did interact with PXR. The CoRNR 
peptides that interacted with any PXR complex in profiles B, C, or D did contain the 
corepressor motif (underlined); however, many also contained internal LxxLL-like motifs 
(red). Many of these motifs were further supported by a -3 polar residue (blue), a -2 
proline (green), and a -1 hydrophobic residue (yellow). (In this figure the identical 
peptide sequences were not listed multiple times.) 
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pM_R_C3         MGSSVWVVNTDLDALIRSELLKGRGEKSSS
pM_alone_L18    MGSRLMLENPLLAQLLGAELPSQSSS
pM_alone_L19    MGSRPWFDNPLLFKLLSEESHESSSS
 
Figure 2.10. Three of the peptides demonstrated interaction profile E. The -3 polar 
residue was asparagines in each sequence. When present, the -2 proline is shown in green 
and the -1 hydrophobic residue is shown in yellow. 
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MGSSYSDTAHTLTPIIRSMLLPSFPNTSSS
MGSSVSYYGANLNPIIRGYLTGGMWSMSSS
MGSSYKQWNHQLSTHIKNPIQPTVTKHSSS
MGSSTDVWSTYLSNLIRAQLNANPSQTSSS
MGSSHPILRDMLTNNIDPQIRETEGPLS*
MGSRGPSDFPILWNLLTTSVSGDSSS
MGSRLSALYPELSRLLSVDVHALSSS
MGSRGDLKCTMLASLLTDCSVASSSS
MGSSNGSDYQILRQLLASEQLLLSSS
MGSSISYEHPLLTGLLLEQRHVDSSS
MGSSLESLYPELYQLLSPGKLSLSSS*
 
Figure 2.11. Peptide sequences that did not interact with full-length PXR in 
mammalian two-hybrid system. The above peptide sequences did not interact in the 
mammalian two-hybrid assay. Sequences marked with asterisks are identical to other 
constructs that did interact in the assay. LxxLL-like motifs are shown in red, -3 polar 
residues in blue, -2 proline in green, and -1 hydrophobic residues in yellow. 
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ELISA Results from Phage from Three Libraries Panned against 
Full Length PXR in the Presence and Absence of Agonist
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Figure 2.12. ELISA results for pans of LxxLL, XLX, and C-S libraries with full-
length PXR in the presences and absence of agonist. Full-length PXR was 
immobilized on a 96 well plate and incubated with phage isolated from sequential 
panning prior to washing and immunodetection.  
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Abstract 
 
The human nuclear receptor pregnane X receptor (PXR) responds to a wide 
variety of potentially harmful chemicals and coordinates the expression of genes central 
to xenobiotic and endobiotic metabolism.  Structural studies reveal that the PXR ligand 
binding domain (LBD) uses a novel sequence insert to form a homodimer unique to the 
nuclear receptor superfamily.  Terminal β-strands from each monomeric LBD interact in 
an ideal antiparallel fashion to bury potentially exposed surface β-strands, generating a 
ten-stranded intermolecular β-sheet.  Conserved tryptophan and tyrosine residues lock 
across the dimer interface and provide the first tryptophan-zipper (Trp-Zip) interaction 
observed in a native protein.  We show using analytical ultracentrifugation that the PXR 
LBD forms a homodimer in solution. We further find that removal of the interlocking 
aromatic residues eliminates dimer formation but does not affect PXR’s ability to interact 
with DNA, RXRα, or ligands.  Disruption of the homodimer significantly reduces 
receptor activity in transient transfection experiments, however, and effectively 
eliminates the receptor’s recruitment of the transcriptional coactivator SRC-1 both in 
vitro and in vivo. Taken together, these results suggest that the unique Trp-Zip-mediated 
PXR homodimer plays a role in the function of this nuclear xenobiotic receptor. 
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Introduction 
The human pregnane X receptor PXR plays a important role in controlling the 
expression of genes central to drug and endobiotic metabolism, including those encoding 
cytochrome P450s (CYPs), UDP-glucuronosyl-transferases, glutathione-S-transferases, 
and drug efflux pumps (Gardner-Stephen, D., et al. 2004; Geick, A., et al. 2001; Gerbal-
Chaloin, S., et al. 2002; Kliewer, S.A. 2003; Xie, W., et al. 2001a).  PXR is considered to 
be a master regulator of the expression of CYP 3A4 isoform, which metabolizes more 
than 50% of human drugs (Maurel, P. 1996).  PXR is expressed largely in the liver and 
intestines and responds to a wide variety of structurally distinct endobiotic and xenobiotic 
compounds, including pregnenolone, progesterone, lithocholic acid, paclitaxel, 
rifampicin, and the St. John’s wort constituent hyperforin (Bertilsson, G., et al. 1998; 
Kliewer, S.A., et al. 1998; Lehmann, J.M., et al. 1998; Moore, L.B., et al. 2000; 
Wentworth, J.M., et al. 2000).  The activation of this xenobiotic sensor has also been 
linked to clinically-relevant drug interactions.  For example, in patients taking the 
unregulated herbal antidepressant St. John’s wort, which contains the potent PXR agonist 
hyperforin (Moore, L.B., et al. 2000; Wentworth, J.M., et al. 2000),  the upregulation of 
drug metabolism genes has been observed to generate significant decreases in the serum 
levels of therapeutics including oral contraceptives, anti-viral compounds, and 
immunosuppressant (Ernst, E. 1999; Fugh-Berman, A. 2000; Piscitelli, S.C., et al. 2000; 
Ruschitzka, F., et al. 2000).   
PXR is a member of the nuclear receptor (NR) superfamily of ligand-activated 
transcription factors, which includes receptors for estrogen, progesterone, retinoid and 
thyroid hormones as well as retinoids, cholesterol metabolites and vitamins.  Many 
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nuclear receptors bind to dual DNA response elements of various arrangements as either 
homodimers or as heterodimers with the retinoid X receptor-alpha (RXRα) (Aranda, A., 
et al. 2001; Giguere, V. 1999).  In the absence of activating ligand, NRs have been shown 
to associate with transcriptional corepressors, which down-regulate gene expression by a 
variety of mechanisms including histone deacetylation (Aranda, A., et al. 2001; 
Rosenfeld, M.G., et al. 2001).  In response to an activating ligand, however, NRs interact 
with transcriptional coactivators that up-regulate target gene expression in part by histone 
acetylation and by facilitating the recruitment of the basal transcriptional machinery 
(Aranda, A., et al. 2001; Rosenfeld, M.G., et al. 2001). PXR functions as a heterodimer 
with RXRα and has been shown to bind to a variety of dual DNA response elements 
arranged as direct and everted repeats.  Upon ligand activation, PXR recruits several of 
the p160-class of transcriptional coactivators, including the steroid receptor coactivator-1 
(SRC-1) (Bertilsson, G., et al. 1998; Blumberg, B., et al. 1998; Kliewer, S.A., et al. 1998; 
Lehmann, J.M., et al. 1998).  For its potent control of CYP3A4 expression, PXR has been 
shown to employ two DNA response elements, one proximal (bases -172 to -149) and 
one distal (bases -7836 to -7607) relative to the start site of transcription.  Both are 
required for maximal induction of gene expression in response to ligands (Goodwin, B., 
et al. 1999).  PXR has also been shown to regulate the expression of MDR1 and CYP 
isoform 2B6 by using a combination of proximal and distal DNA response elements 
(Geick, A., et al. 2001; Wang, H.B., et al. 2003).   
  The PXRs of known sequence contain a ~50-amino acid insert unique to members 
of the nuclear receptor superfamily.  This region is located between helices 1 and 3 within 
the canonical NR LBD fold, and adds a novel helix 2 and two β-strands adjacent to 
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PXR’s ligand binding cavity.  Numerous crystal structures of the human PXR LBD have 
also revealed that the novel β-turn-β motif of this insert extends the two- to three-
stranded antiparallel β-sheet common to NRs to a five-stranded β-sheet in PXR 
(Chrencik, J.E., et al. 2005; Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; 
Watkins, R.E., et al. 2003b).  It is the terminal β-strands in each of these β-sheets that 
associate in an antiparallel fashion to generate the PXR homodimer, which produces a 
ten-strand intermolecular antiparallel β-sheet (Figure 1.2A).  No other nuclear receptor 
has been observed to homodimerize in this fashion.  In this work, structural, biophysical 
and functional features of this PXR homodimer are examined.  Using sedimentation 
equilibrium experiments, the PXR LBD is shown to form a homodimer in solution with a 
Kd of 4.5 μM.  Key residues at the dimer interface are also mutated and shown to disrupt 
formation of the PXR dimer, which significantly reduces transcriptional activity and 
coactivator recruitment without impacting other necessary receptor actions like RXRα, 
DNA and ligand binding.  Taken together, the data presented suggest that the Trp-Zip-
mediated PXR homodimer interface plays a potential role in receptor function.  
 
Experimental Procedures 
 
PXR Expression and Purification   
Wild-type human PXR LBD (residues 130-434) was coexpressed with a fragment 
of SRC-1 (residues 623-710) in E. coli BL21 (DE3) and purified using nickel-affinity 
chromatography as previously described (Watkins, R.E., et al. 2001).  The 
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Trp223Ala/Tyr225Ala PXR LBD double-mutant was generated using the QuikChange 
mutagenesis kit (Stratagene), and expressed under the same conditions as wild-type PXR, 
but formed inclusion bodies in E. coli.  The inclusion body pellet was washed twice with 
buffer containing 0.5% Triton X-100, 20 mM Tris-Cl pH 7.5, 250 mM NaCl, 50 mM 
imidazole, and 5% glycerol.  Following the Triton X-100 wash, the pellet was 
resuspended in 6 M guanidinium hydrochloride pH 7.5 with the addition of 10 mM β-
mercaptoethanol (BME), and stirred at 4 °C for 30 min.  The denatured protein was ultra-
centrifuged at 28.8K rpm for 30 min, diluted 1:3 with buffer (20 mM Tris-Cl pH 7.5, 250 
mM NaCl, 50 mM imidazole, 10 mM BME and 5% glycerol) and then refolded by 
dialysis against this buffer with four changes.  The refolded mutant protein was then 
purified under the same conditions as wild-type PXR LBD. In preparation for analytical 
ultracentrifugation, protein samples were concentrated to ~2.0 mg / ml and dialyzed 
(1:1000 (v/v) protein to dialysate) overnight with two buffer changes.  The dialysis buffer 
(20mM Tris-Cl pH 7.5, 250mM NaCl, 2.5 mM EDTA, 5mM BME and 5% glycerol) was 
used to dilute protein to relevant concentrations.  The cholesterol drug SR12813 (Sigma) 
was added at a 4-fold molar excess.    
 
Analytical Ultracentrifugation   
Sedimentation equilibrium experiments were performed using a Beckman XL-A 
analytical ultracentrifuge equipped with scanning absorption optics.  Equilibrium 
measurements were obtained at three different rotor speeds (9,000, 13,000 and 16,000 
rpm) and three concentrations (8.6, 17.3 and 21.7 μM) for wild-type PXR LBD and 
Trp223Ala/Tyr225Ala PXR LBD in triplicate.  Baseline absorbance offsets were 
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established by increasing the rotor speed to 45,000 rpm for 6 hrs.  Sedimentation 
equilibrium data was analyzed using the Beckman XL-A/XL-I data Analysis Software 
Version 4.0 which uses a nonlinear curve fitting procedure to determine the weight-
average monomer molecular weight  M and the association constant Ka according to the 
following equation: 
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where cr is the concentration at radial position r, 0,rmonc is the concentration of the 
monomer at the reference radius 0r , ω is the angular velocity in radians per second, R is 
the universal gas constant (8.314 x 107 erg·mol-1·K-1), T is the temperature in Kelvin, M is 
the monomer molecular weight, ν is the partial specific volume, ρ is the density of the 
solvent, and Ka is the association constant, and E is the baseline offset.  The association 
constant, Ka was converted to the dissociation constant Kd by the following equation:  
εbKK ad
2=  
where b is the path length (1.2 cm) and ε is the molar extinction coefficient (28,390 M-1 
cm-1 for PXR LBD) determined using the program Protean TM.   
 
Circular Dichroism Spectropolarimetry  
To confirm that the Trp223Ala/Tyr225Ala double-mutant form of the PXR LBD 
was properly folded, circular dichroism spectropolarimetry (CD) was performed using an 
Applied Photophysics PiStar-180 CD spectropolarimeter.  The ellipticity from 210-300 
nm was measured for wild-type PXR LBD and for the Trp223Ala/Tyr225Ala PXR LBD 
double-mutant.  Both proteins were at 0.2 mg ml-1 in 100 mM phosphate buffer, pH 7.8, 
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100 mM NaCl and 5% glycerol.  To examine thermal melting temperatures, the 
temperature was ramped from 20 to 98 ˚C while monitoring the ellipticity at 222 nm. 
Plots of fraction denatured versus temperature were produced by defining the upper and 
lower temperature baselines as 0 and 100%, respectively.  Melting temperatures (Tm’s) 
were defined as the point at which 50% of the sample denatured. Trials were performed 
in triplicate, and Tm’s for individual runs were averaged and standard errors calculated. 
 
Transient Transfection Assays   
Mutations in full-length PXR were generated with the Stratagene QuikChange site 
directed mutagenesis kit according to the manufacturer's instructions.  Transfections were 
performed as described previously (Goodwin, B., et al. 1999; Watkins, R.E., et al. 2001).  
Briefly, CV-1 cells were plated in 96-well plates in phenol red-free Dulbecco’s modified 
Eagle’s medium containing high glucose and supplemented with 10% charcoal/dextran 
treated fetal bovine serum (HyClone, Logan, UT).  Transfection mixes contained 5 ng of 
receptor expression vector, 20 ng of reporter plasmid, 12 ng of β-actin SPAP as internal 
control, and 43 ng of carrier plasmid.  Plasmids for wild-type and mutant forms of human 
PXR and for the XREM-CYP3A4-LUC reporter, containing the enhancer and promoter 
of the CYP3A4 gene driving Luciferase expression, were as previously described 
(Goodwin, B., et al. 1999).  Transfections were performed with LipofectAMINE (Life 
Technologies, Inc., Grand Island, NY) essentially according to the manufacturer’s 
instructions.  Drug dilutions of rifampicin (Sigma, St. Louis, MO) and SR12813 
(synthesized in-house) were prepared in phenol red-free Dulbecco’s modified Eagle’s 
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medium/F-12 medium with 15 mM HEPES supplemented with 10% charcoal-stripped, 
delipidated calf serum (Sigma, St. Louis, MO) which had previously been heat-
inactivated at 62°C for 35 minutes.  Serial drug dilutions were performed in triplicate to 
generate 11-point concentration response curves.  Cells were incubated for 24 hours in 
the presence of drugs, after which the medium was sampled and assayed for alkaline 
phosphatase activity.  Luciferase reporter activity was measured using the LucLite assay 
system (Packard Instrument Co., Meriden, CT) and normalized to alkaline phosphatase 
activity.  EC50 values were determined by standard methods. 
 
Immunocytochemistry   
CV-1 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
plus 10% charcoal-stripped calf serum (Hyclone, Logan, UT).  The day before 
transfection, cells were plated at 2 x 105 cells per well of a 6 well plate (Becton 
Dickinson, Franklin Lakes, NJ) on ethanol-washed glass cover slips (Fisher Scientific, 
Pittsburgh, PA).  Transfection was carried out using Effectene (Qiagen, Valencia, CA) 
according to the manufacturer’s specifications, with plasmids expressing wild-type PXR, 
Trp223Ala/Tyr225Ala PXR, or carrier DNA.  Transfection complexes were suspended in 
phenol red-free DMEM/F12 plus 10% charcoal-stripped, delipidated calf serum (Sigma, 
St. Louis, MO), and left in contact with the cells overnight.  The medium was then 
replaced, drugs [10 μM rifampicin (Sigma, St. Louis, MO) or 2 μM SR12813 
(synthesized in house)] or 0.1% DMSO (Sigma, St. Louis, MO) were added, and the 
incubation was continued for a further 6 hours.  For immunofluorescent staining of 
exogenous proteins, cultures were placed on ice for 5 minutes, rinsed 3 times with cold 
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PBS, then the cover slips were immersed in ice-cold acetone for 5 minutes and air-dried. 
Nonspecific antibody binding was blocked by incubating for 10 minutes in PBS 
containing 10% normal donkey serum (Jackson Immunoresearch Labs, West Grove, PA).  
Goat anti-PXR (Santa Cruz Biotechnology, Santa Cruz, CA) was applied in blocking 
buffer for 1 hour at a dilution of 1:100.  The secondary antibody, donkey anti-goat IgG 
labeled with ALEXA 488 (Molecular Probes, Eugene, OR), was also applied for one hour 
in blocking buffer, but at a dilution of 1:1,000.  Cultures stained without primary 
antibody were also obtained.  Cover slips were mounted in 90% glycerol (Sigma, St. 
Louis, MO), 10% PBS, 4% n-propyl gallate (Sigma, St. Louis, MO) and 0.2 μM Hoechst 
33258 (Molecular Probes, Eugene, OR).  Fluorescent images were obtained on a Zeiss 
Axiovert 100 TV inverted microscope with a 100x objective under oil immersion, using 
Zeiss Axiovision software (Carl Zeiss, Inc., Thornwood, NY).  
 
Gel Mobility Shift Assays   
Gel mobility shift assays were performed as described before (Honkakoski, P., et 
al. 1998).  Full-length human wild-type PXR, double-mutant (Trp223Ala/Tyr225Ala) 
PXR, and RXRα proteins were synthesized using the TNT quick-coupled in vitro 
transcription/translation system (Promega).  Probes NR3 and ER6 from CYP2B6 and 
CYP3A4, respectively, were labeled with [γ-32P]dATP and purified by Microspin G-25 
columns (Amersham Biosciences).  Typically, 10 μL of binding reactions contained 10 
mM HEPES (pH 7.6), 0.5 mM dithiothreitol, 15% glycerol, 0.05% Nonidet P-40, 50 mM 
NaCl, 2 μg of poly(dI-dC), with 0.1, 0.5, or 1 μL of in vitro translated nuclear receptor 
protein, and 4 X 104 cpm of labeled probe.  After incubation at room temperature for 10 
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min, reaction mixtures were resolved on 5% acrylamide gels in 1 X Tris-acetic acid, 
EDTA buffer at 180 V for 1.5 h.  Afterward, gels were dried, and autoradiography was 
performed overnight at -70 ˚C. 
 
Competition Ligand Binding Assay   
Polylysine YiO imaging beads (Amersham, GE Healthcare) were coated with 
histidine-tagged WT PXR LBD or Trp223Ala/Tyr225Ala PXR LBD, by mixing for 60 
minutes at room temperature, in Tris buffer pH 8.0.  Non-specific binding sites were 
blocked with a ten-fold excess of BSA for an additional 60 minutes at room temperature.  
The bead/receptor mix was washed and reconstituted in fresh assay buffer (50 mM Tris 
pH 8.0 containing 10% glycerol, 200mM KCl, 50uM CHAPS, 0.1 mg/mL BSA and 2mM 
DTT).  Biotin (0.1 mM) was added to the suspension and allowed to mix for a further 60 
minutes.  The blocked receptor bead-mix was centrifuged at 1000 x g for 10 minutes at 
4°C.  The supernatant was discarded and the receptor-bead pellet was re-suspended in the 
appropriate volume of assay buffer. [N-methyl-3H]-GW0438X (synthesized at GSK and 
custom labeled at Amersham Biosciences, UK) was added to this suspension to achieve a 
final concentration of 10 nM.  The receptor/imaging bead/radioligand mix was added 
directly to test compounds in 384-well plates in a one step addition.  Test compounds 
were prepared from powder stocks by dissolving in DMSO and then serially diluted for 
displacement curves.  Displacement of 10 nM [N-methyl-3H]-GW0438 was measured in 
a Viewlux 1430 ultraHTS microplate imager (Perkin Elmer Wallac Inc).  Non-specific 
binding was determined in the presence of 10 μM GW0438.  A similar competitive ligand 
binding assay method is described elsewhere (Nichols, J.S., et al. 1998).  Data analysis 
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was achieved using a 3 parameter fit, assuming a slope of 1.  The data were calculated as 
pIC50’s, but because the ligand concentration was well below the Kd for the receptor, this 
value was not different from the pKi.  The pKi is the –log of Ki, the inhibitor 
concentration at which 50% inhibition is observed.  Ki is calculated from the IC50 using 
the Cheng-Prusoff equation:  
Ki = IC50 / 1+([L]/Kd) 
where L = concentration of free radioligand used in the assay and Kd = dissociation 
constant of the radioligand for the receptor .   
 
Pull-Down Assays   
Pull-down studies were performed using a Profound Pull-Down kit (Promega) at 
4 °C according to the manufacturer’s instructions.  For the PXR-RXRα interaction, the 
RXRα-LBD (residues 225-462) was cloned into the pMALCH10T vector, expressed in 
E.coli BL21pLysS cells and purified by nickel affinity chromatography as described 
elsewhere (Ortlund, E.A., et al. 2005).  Purified RXRα-LBD was biotinylated using an 
EZ-Link Sulfo-NHS-LC-Biotinylation kit (Promega) according to the manufacturer’s 
instructions.  Biotinylated RXRα-LBD at 0.2 mg / mL was immobilized on streptavidin-
agarose beads.  The beads were washed with TBS buffer (25 mM Tris-Cl pH 7.0, 150mM 
NaCl), then blocked with biotin solution.  The beads were equilibrated with binding 
buffer (50mM Tris-Cl pH 7.8, 250mM NaCl, 2.5 mM EDTA, and 5% glycerol) and wild-
type (WT) PXR LBD or Trp223Ala/Tyr225Ala PXR LBD at 0.2 mg / mL was added to 
the beads and incubated for 12 hrs.  Following prey capture, the beads were washed with 
binding buffer, eluted with elution buffer at pH 2.8, and examined by SDS-PAGE.  For 
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the PXR-SRC-1 peptide interaction, biotinylated SRC-1 or random peptides at 0.2 mg / 
mL were immobilized on streptavidin-agarose beads.  The beads were washed with TBS 
buffer (25 mM Tris-Cl pH 7.0, 150mM NaCl), then blocked with biotin solution.  The 
beads were equilibrated with binding buffer (50mM Tris-Cl pH 7.8, 250mM NaCl, 10% 
glycerol, 0.5% Triton X-100) and WT PXR LBD or Trp223Ala/Tyr225Ala PXR LBD at 
0.2mg / mL was added to the beads and incubated for 12 hrs.  Following prey capture, the 
beads were washed with binding buffer, eluted with buffer at pH 2.8, and examined by 
SDS-PAGE.   
 
Mammalian Two-Hybrid Studies   
HepG2 cells were cultured in minimal essential medium (MEM) (Invitrogen) 
containing 10% fetal bovine serum albumin supplemented with 0.1 mM non-essential 
amino acids and 1 mM sodium pyruvate.  1000 ng of VP16_PXR (full-length WT PXR or 
Trp223Ala/Tyr225Ala PXR), 1000 ng of pM_SRC-1 NRID (nuclear receptor interaction 
domain I; SRC-1 residues 621-765), 900 ng 5xGal4Luc3 reporter plasmid (Chang, C., et 
al. 1999) and 100 ng pCMVB-gal (for normalization) were used for transfections 
performed in triplicate.  Transfections were achieved with Lipofectin according to the 
manufacturer’s instructions (Invitrogen).  Equal levels of PXR and RXRα protein 
expression in transfected HepG2 cells was confirmed by Western analysis (data not 
shown).  Cells were treated with 1 μM SR12813 sixteen hrs after transfection.  Twenty-
four hours after ligand treatment, cells were lysed and assayed for luciferase and β-
galactosidase activity (Norris, J., et al. 1995).      
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Results 
 
The PXR LBD Forms a Unique Homodimer   
The human PXR ligand binding domain (PXR LBD) forms either a 
crystallographic or non-crystallographic homodimer in all structures determined to date 
(Chrencik, J.E., et al. 2005; Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; 
Watkins, R.E., et al. 2003b).  The homodimer interface is formed in large part by the β1′ 
strands from each monomer, which interact in an ideal anti-parallel fashion to generate a 
ten-stranded intermolecular β-sheet (Figures 1.2A and 3.1) (Watkins, R.E., et al. 2003a).  
The β1 and β1′ strands of the PXR LBD are part of the ~50 amino acid insert novel to the 
PXRs relative to other members of the nuclear superfamily.  In addition to six main-chain 
to main-chain intermolecular hydrogen bonds, interdigitating tryptophan (Trp223) and 
tyrosine (Tyr225) residues from each monomer lock across the dimer interface (Figure 
3.1). It has been shown that tryptophan and tyrosine residues tend to cluster at protein-
protein interaction “hot spots” (Bogan, A.A., et al. 1998; DeLano, W.L. 2002).  Pro175 
from the loop that follows α1 helps to bury these aromatic side chains, and forms a 
hydrogen bond between its main-chain carbonyl oxygen and the indol nitrogen on 
Trp223.  The residues involved in this dimer interface are largely conserved in the PXRs 
of known sequence, including those from human, rhesus monkey, pig, dog, rabbit, mouse 
and rat.  The only exception is dog PXR, which contains a glutamine in place of Trp223; 
however, glutamine in this position could still hydrogen bond with Pro175 and 
interdigitate with Tyr225.  The formation of the PXR homodimer buries 1,610 Å2 of 
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solvent accessible surface area, which is sufficient to suggest physiological relevance (Lo 
Conte, L., et al. 1999).   
 
The PXR LBD Forms a Homodimer in Solution   
Sedimentation equilibrium experiments were performed with wild-type PXR LBD 
to determine whether the homodimer observed in crystal structures is also formed in 
solution. Experimental data were collected at three speeds (9,000, 13,000 and 16,000 
rpm) and three protein concentrations (8.6, 17.3 and 21.7 μM) using a Beckman XL-A 
analytical ultracentrifuge.  When data were fit to a single species model, the molecular 
weight determined was 67.2 kDa (for n = 9 data sets), which is nearly 2 times the 
molecular weight of the monomer PXR LBD (36.2 kDa; Table 3.1).  The subsequent 
application of a monomer-dimer equilibrium model produced more random residuals and 
provided the optimal fit for the experimental data, and generated a dissociation constant 
of 4.5 ± 0.8 μM (Figure 3.2A).  Experiments repeated in the presence of the PXR agonist 
SR12813 yielded a similar Kd value of 3.9 ± 1.2 μM using the same monomer-dimer 
equilibrium model.   
We next examined the impact that replacing the interlocking aromatic residues at 
the dimer interface with alanines would have on receptor LBD dimerization.  Thus, a 
Trp223Ala/Tyr225Ala PXR LBD double-mutant was tested by analytical 
ultracentrifugation using the same speeds and protein concentrations.  These data fit well 
to a single species model and indicated a measured molecular weight of 36.3 kDa, nearly 
identical to the calculated molecular weight for the PXR LBD of 36.2 kDa (Figure 3.2B).  
Possibly due to its inability to form a stabilizing dimer, the Trp223Ala/Tyr225Ala double-
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mutant form of the PXR LBD formed inclusion bodies during protein expression in E. 
coli cells and had to be refolded using guanidinium hydrochloride to conduct these 
ultracentrifugation studies.  To confirm that this refolded double-mutant form of the PXR 
LBD was properly folded, we performed circular dichroism (CD) spectropolarimetry 
experiments.  The CD spectrum from 210-300 nm for the Trp223Ala/Tyr225Ala PXR 
LBD double-mutant was identical to the spectrum of the wild-type PXR LBD (data not 
shown), indicating that both proteins have the same secondary structural features.  We 
also measured the melting temperatures (Tm) of the wild-type and double-mutant forms 
of the PXR LBD using CD spectropolarimetry monitored at 222 nm.  The Tm’s of wild-
type PXR LBD and the Trp223Ala/Tyr225Ala PXR LBD double-mutant were 43.0 ± 0.8 
and 39.8 ± 0.5, respectively (data not shown).  These data indicate that the overall fold 
and stability of the double-mutant and wild-type forms of the PXR LBD are similar.  
Indeed, as shown below, the same refolded PXR double-mutant LBD was able to bind to 
RXRα LBD in vitro, which further supports the conclusion that it retains a wild-type 
structure overall.  Taken together, these results establish that mutation of the 
interdigitating aromatic residues at the PXR dimer interface eliminates dimer formation 
in solution.  
We also conducted sedimentation equilibrium experiments in the presence of a 
peptide of the sequence NH3-GSVWNYKP-CO2, which mimics the dimer interface in 
PXR.  Data analysis indicated that PXR dimerization was partially inhibited by the 
presence of this peptide.  The molecular weight of the PXR LBD measured in the 
presence of 10-fold molar excess peptide was 70.0 kDa, whereas the molecular weight 
determined in the presence of 20-fold molar excess peptide (172, 346, or 434 μM) was 
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50.3 kDa (Table 3.1).  Thus, the PXR LBD homodimer interaction can be disrupted in 
solution using relatively high concentrations of an eight amino acid peptide 
corresponding in sequence to the dimer interface.   
 
Dimer Interface Residues and Transcription   
To examine the impact of dimer interface mutations on PXR function, Trp223Ala 
and Tyr225Ala alterations were introduced into full-length PXR and the activation of a 
luciferase reporter gene under control of the CYP3A4 promoter was examined in CV-1 
cells.  As expected, robust up-regulation in these transient transfection experiments was 
observed for wild-type PXR in the presence of the agonists SR12813 and rifampicin 
(Figures 3.3A,B).  However, all mutant forms of the receptor were found to be 
significantly reduced in their ability to respond to ligands, and exhibited no basal (ligand-
independent) transcriptional activation.  While the single-site mutant Trp223Ala was 
found to be more responsive to SR12813 and rifampicin than the Tyr225Ala single 
mutant, the Trp223Ala/Tyr225Ala double-mutant exhibited little response to SR12813 
and essentially no response to rifampicin (Figures 3.3A,B).  These results indicate that 
mutations that eliminate PXR homodimer formation significantly reduce the ability of the 
receptor to upregulate gene expression in ligand-dependent and -independent fashions.   
To confirm the proper sub-cellular trafficking of the Trp223Ala/Tyr225Ala 
double-mutant form of PXR, immunocytochemistry techniques were employed in CV-1 
cells, the same cell type used for transfection assays.  Wild-type full-length PXR 
translocated to the nucleus of CV-1 cells both in the absence of agonist and in the 
presence of either rifampicin or SR12813 (Figure 3.4A).   Similarly, the 
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Trp223Ala/Tyr225Ala double-mutant PXR was also found to translocate to the nucleus in 
the absence of ligand and in the presence of either rifampicin or SR12813 (Figure 3.4A).  
These results confirm that the dramatic changes in transcriptional activity observed for 
the mutant forms of PXR in transient transfection assays are not caused by improper 
subcellular localization relative to wild-type PXR.   
 
Monomeric PXR Binds Ligands, DNA and RXRα  
We next examined whether the Trp223Ala/Tyr225Ala double-mutant form of 
PXR, which is incapable of homodimerizing and activating transcription, was able to 
perform basic molecular functions critical to nuclear receptor action.  First, the ability of 
the double-mutant PXR LBD to interact with ligands was examined in a radioligand 
competition assay.  Both wild-type and double-mutant PXRs bound equally well to the 
agonists SR12813, rifampicin, estradiol and 5β-pregnane-3,20-dione (Table 3.2).  
Second, gel mobility shift assays were employed to investigate DNA binding.  
Heterodimeric complexes of full-length RXRα with either full-length wild-type or 
double-mutant PXRs bound strongly to NR3 and ER6 DNA elements (Bertilsson, G., et 
al. 1998; Blumberg, B., et al. 1998; Lehmann, J.M., et al. 1998; Wang, H.B., et al. 2003) 
(Figure 3.4B).  Third, the ability of the double-mutant PXR LBD to interact with the 
LBD of its physiological heterodimer partner RXRα was examined using in vitro pull-
down assays (Figure 3.4C).  Both wild-type and double-mutant PXR LBDs were found 
to form complexes with biotinylated RXRα LBDs.  Taken together, these results 
demonstrate that the Trp223Ala/Tyr225Ala double-mutant PXR retains many of its key 
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molecular functions: its ability to associate with ligands, with its functional heterodimer 
partner RXRα, and with DNA.  
 
Monomeric PXR Cannot Recruit Coactivator   
Because mutant forms of PXR were transcriptionally compromised both alone 
and in the presence of agonists, the recruitment of the transcriptional coactivator SRC-1 
by the double-mutant PXR was examined using two approaches.  First, in mammalian 
two-hybrid studies, the ability of wild-type and Trp223Ala/Tyr225Ala double-mutant 
full-length PXRs to interact with the nuclear receptor interaction domain (NRID) of SRC-
1 in HepG2 cells was tested.  It was found that wild-type PXR efficiently complexed with 
SRC-1, an interaction that was enhanced by the presence of agonist SR12813; however, 
the Trp223Ala/Tyr225Ala double-mutant PXR failed to interact with SRC-1 either alone 
or with SR12813 (Figure 3.5A).  Second, the same interaction was examined in vitro 
using pull-down assays with a biotin-labeled SRC-1 peptide.  Similar to the in vivo 
experiments, only wild-type PXR LBD was observed to complex with the SRC-1 peptide, 
and this interaction was significantly improved by the presence of SR12813.  In contrast, 
double-mutant PXR LBD was incapable of interacting with the same peptide, even in the 
presence of SR12813 (Figure 3.5B).  Thus, the inability of Trp223Ala/Tyr225Ala 
double-mutant PXR to activate transcription appears to be the result of a defect in binding 
to p160-type coactivators like SRC-1.  These results suggest that the unique PXR 
homodimer formed is involved in coactivator recruitment by the receptor. 
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Discussion 
 
In all crystal structures of the ligand binding domain of human PXR examined to 
date, the protein forms a homodimer involving amino acids unique to PXR.  The 
dimerization interface is essentially created by the association of the β1’ strands of each 
monomer in an ideal antiparallel fashion, which generates a ten-stranded antiparallel 
inter-molecular β-sheet (Figure 1.2A).  The β1 and β1’ strands of PXR are on a ~50-
residue insert that is unique in sequence and structure in the nuclear receptor superfamily.  
In this report, we show that the LBD of human PXR forms a homodimer in solution by 
sedimentation equilibrium studies, and that a double-mutant form of PXR, in which key 
aromatic residues at the dimer interface are eliminated, is an obligate monomer (Table 
3.1; Figure 3.2).  The mutations at the interface (Trp223Ala and Tyr225Ala) also 
severely impact the response of full-length human PXR to the agonists SR12813 and 
rifampicin in transient transfections (Figure 3.3).  These mutations do not prevent full-
length PXR from entering the nucleus, or from binding to DNA, ligands or RXRα 
(Figure 3.4; Table 3.2).  Significantly, however, they do prevent PXR from associating 
with the transcriptional coactivator SRC-1 in both mammalian two-hybrid studies in vivo 
and in pull-down experiments in vitro (Figure 3.5).  Indeed, the loss of basal activity by 
the Trp223Ala and Tyr225Ala variant forms of the receptor likely reflects the inability of 
the unliganded mutant PXR-RXRα heterodimers to recruit sufficient coactivator to 
promote a low level of gene expression.  Similar “long-range” effects have recently been 
observed in the monomeric nuclear receptor human liver receptor homologue-1, in which 
disruption of the position of a non-DNA binding helix in the DNA binding domain of this 
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receptor significantly impacts coactivator recruitment by the distantly-located ligand 
binding domain (Solomon, I.H., et al. 2005).  In summary, the accumulated data 
presented here suggest that the PXR homodimer may play a role in the proper 
physiological function of this nuclear xenobiotic receptor. 
The interlocking tryptophan and tyrosine residues that form the PXR dimer 
interface represent the first tryptophan zipper (TrpZip) observed in a native protein. 
TrpZips have been examined extensively in the design of stable peptide sequences that 
form predictable secondary structures (Cochran, A.G., et al. 2001; Russell, S.J., et al. 
2000), and it was found that Trp-Trp pairs placed in designed β-hairpins formed the most 
stable structures of all combinations of amino acids examined (Cochran, A.G., et al. 
2001).  We superimposed the homodimer interface of human PXR with the nuclear 
magnetic resonance (NMR) structure of TrpZip4, a designed β-hairpin structure 
containing tryptophan zippers.  The two tryptophans and two tyrosines in PXR line up 
well with the four tryptophans in TrpZip4; in addition, the main-chain regions of this 
native protein dimer and this designed β-hairpin also superimpose well (Figure 3.6A) 
(Cochran, A.G., et al. 2001).  A search of the Protein Data Bank 
(http://www.rcsb.org/pdb/) yielded only one other possible naturally occurring TrpZip in 
a β-sheet dimer interface, the E2 DNA binding domain of papillomavirus-1.  Trp360 from 
each monomer of the E2 DNA binding domain is in van der Waals contact and 
contributes a major stabilizing effect (Hegde, R.S., et al. 1992).  However, the 
tryptophans in this structure are orthogonal and face to face but do not interdigitate like 
the aromatic residues observed in PXR (Hegde, R.S., et al. 1992). 
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Richardson and Richardson have shown that it is rare for monomeric proteins to 
expose terminal β-strands of a β-sheet (Richardson, J.S., et al. 2002).  Exposed β-strands 
have the potential to form dangerous interactions with other β-strands, leading to intra- or 
intercellular aggregates like amyloid fibers.  Proteins employ a variety of techniques to 
cap the terminal strands of a β-sheet, including covering loops, β-bulges, and the central 
placement of charged residues (Richardson, J.S., et al. 2002).  Nuclear receptors, which 
typically contain a two- to three-stranded antiparallel β-sheet, use several of these 
methods to cap their terminal β-strands.  The PPARs, for example, use a short terminal β-
strand, a proline that introduces a kink just prior to the β-strand, and a capping α-helix 
(Nolte, R.T., et al. 1998).  Similarly, CAR, which is structurally and functionally related 
to PXR, caps its terminal β-strand with a short α-helix (Figure 3.6B) (Shan, L., et al. 
2004; Suino, K., et al. 2004; Xu, R.X., et al. 2004).  RXRα, LXR and VDR all employ 
loops or helices that cap their terminal β-strands, and VDR further places two charged 
residues in the center of the terminal strand to disrupt potential non-specific contacts with 
other β-structures (Gampe, R.T., Jr., et al. 2000b; Rochel, N., et al. 2000; Williams, S., et 
al. 2003).  The observations that PXR leaves the terminal strand in its five-stranded 
antiparallel β-sheet uncapped, and places residues able to form a TrpZip-like structure on 
this exposed strand, support the conclusion that the PXRs evolved to form a homodimer .  
We note, however, that the region of the PXR LBD between residues 178 and 192 has not 
been visualized structurally to date (Figure 1.2B).  It is possible that this stretch of amino 
acids caps the terminal β1’ strand but is displaced when the protein forms a homodimer. 
PXR forms a heterodimer with RXRα to control the transcription of target genes.  
We examined whether the PXR homodimer would interfere with the formation of the 
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PXR-RXRα heterodimer.  Using the crystal structure of the PPARγ-RXRα ligand binding 
domain heterodimer, we replaced the PPARγ LBD with the PXR LBD to generate a 
model of the PXR-RXRα LBD heterodimeric complex that maintained most of the key 
hydrophobic and electrostatic contacts at the interface (Gampe, R.T., Jr., et al. 2000a).  
We also noted that the surfaces used for PXR-RXRα heterodimerization and PXR 
homodimerization do not overlap; thus, a structurally-compelling model for a PXR-
RXRα heterotetramer can be generated (Figure 3.6C).  It is of interest that no PXR-
RXRα heterotetramer was observed in gel mobility shift assays (Figure 3.4B), although 
this is perhaps due to the moderate strength of the dissociation constant (μM) for the PXR 
homodimer interface. There are several potential ways that a PXR-RXRα heterotetramer 
could be involved in receptor function.  First, a heterotetramer could form between the 
two PXR-RXRα heterodimers bound to both the proximal and distal DNA elements in 
the regulatory regions of genes.  Recall that two PXR-RXRα binding elements exist in 
the CYP3A4 promoter, at bases -172 to -149 (proximal) and -7836 to -7607 (distal), and 
that both elements are required for maximal transcriptional activation (Goodwin, B., et al. 
1999).  In this model, both PXR-RXRα heterodimers would be bound to DNA, and the 
DNA would be expected to form a long-range loop to generate the heterotetramer.  
Second, only one PXR-RXRα heterodimer could bind to a DNA element and the second 
heterodimer may simply associate with the first (but not with DNA) to form the 
heterotetramer.  In this case, the role of a PXR-RXRα heterotetramer may be to enhance 
the initial recruitment (and local concentration) of transcriptional coactivators.  Third, the 
heterotetramer may be a crucial trafficking form of the complex required to position the 
proteins appropriately within the nucleus and/or adjacent to euchromatin.  
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The structural basis of the impact that the homodimer interface has on coactivator 
binding may be through the indirect stabilization of αAF and the AF-2 surface.  Ordering 
of the β1-β1’ region by dimerization would be expected to stabilize the pseudohelix α2 
(which starts at residue 198) that bridges the space between the β-sheet and α-helices 10 
and AF in PXR (Figure 1.2A).  Note that β-strands 1 and 1’, as well as α-helix 2, are all 
on the novel sequence insert unique to PXR and, as we have shown, the contacts they 
make appear to be involved in receptor function.  These observations raise the possibility 
that disruption of the PXR homodimer interface by small molecule modulators could 
provide a mechanism to control specifically the regulation of drug metabolism gene 
expression by PXR during the therapeutic treatment of disease. 
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*WTPXR: wild-type PXR. 
N.A.: not applicable. 
 
Table 3.1. Sedimentation Equilibrium Results for PXR LBDs     
Mw,calc for PXR LBD = 36,200 Da   
    Mw,app (Da)   Kd ( x 10-6 M) 
WTPXR*  67,200 ± 3500  4.5 ± 0.8 
WTPXR + SR12813  71,100 ± 2100  3.9 ± 1.2 
WTPXR + 10-fold peptide  70,050 ± 1397  5.3 ± 0.9 
WTPXR + 20-fold peptide  50,317 ± 3022  42.8 ± 13.9 
Trp223Ala/Tyr225Ala PXR   36,300 ± 981   N.A. 
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Table 3.2.  Ligand Binding to PXR LBDs 
 
 
 Wild-Type PXR W223A/Y225A PXR 
 pKi 
 
pKi 
SR12813 5.7 5.6 
Rifampicin 5.3 5.6 
Estradiol 5.8 5.7 
5β-pregnane-3,20-dione 5.0 5.0 
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Figure 3.1. PXR LBD homodimer interface. Detailed view of the PXR LBD 
homodimer interface, rotated 180° about the vertical axis relative to Figure 1A.  Novel 
β1′-strands from each monomer are shown in green and cyan.  Inter-locking tryptophan 
and tyrosine residues from each monomer are rendered in green and cyan, respectively.  
Hydrogen bonding interactions are indicated (dashed or dotted lines), as are Van der 
Waals contacts (solid arrows). 
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Figure 3.2A. Sedimentation 
equilibrium data for wild-type 
human PXR LBD.  Each graph 
indicates a single concentration (left: 
8.6 μM, center: 17.3 μM, right: 21.7 
μM) collected at 9,000 rpm (circles), 
13,000 rpm (squares) and 16,000 rpm 
(triangles).  The data in the figure was 
fit to a monomer-dimer equilibrium 
model (solid lines) with the residuals 
for each fit shown in the upper panels.                               
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Figure 3.2B. Sedimentation 
equilibrium data for mutant human 
PXR LBD (Trp223Ala/Tyr225Ala).  
Each graph indicates a single 
concentration (left: 8.6 μM, center: 
17.3 μM, right: 21.7 μM) collected at 
9,000 rpm (circles), 13,000 rpm 
(squares) and 16,000 rpm (triangles). 
Sedimentation equilibrium data 
obtained for Trp223Ala/Tyr225Ala 
mutant PXR.  The data in the figure 
were fit to a singles species model 
(solid lines) with the residuals for each 
fit shown above. 
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Figure 3.3A. Transcriptional activity of wild-type and mutant PXR in the presence 
of SR12813. Transient transfections in CV-1 cells using a luciferase reporter construct 
and wild-type or mutant forms of full-length human PXR.  Responses in the presence of 
increasing concentrations of SR12813 is shown. 
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Figure 3.3B. Transcriptional activity of wild-type and mutant PXR in the presence 
of rifampicin. Transient transfections in CV-1 cells using a luciferase reporter construct 
and wild-type or mutant forms of full-length human PXR.  Responses in the presence of 
increasing concentrations of rifampicin is shown. 
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Figure 3.4A. Cellular localization of full-length mutant and wild-type PXR. Full-
length wild-type PXR (WTPXR) and Trp223Ala/Tyr225Ala double-mutant PXR are 
competent for nuclear translocation in CV-1 cells.  Fluorescence due to specific staining 
of exogenous WTPXR or Trp223Ala/Tyr225Ala PXR in transfected CV-1 cells was 
concentrated in nuclei, as confirmed by colocalization with the nuclear stain Hoechst 
33258 (not shown).  Neither untransfected cells nor transfected cells treated with 
secondary antibody only were stained (not shown).  The general distribution of PXR and 
Trp223Ala/Tyr225Ala PXR within the nuclei was not observed to differ in the presence 
of either rifampicin or SR12813.  
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Figure 3.4B. Mutant PXR binds NR3 and ER6 DNA elements. Full-length 
PXR/RXRα heterodimers containing wild-type or double mutant (Trp233Ala/Tyr225Ala) 
PXR bind to CYP2B6 and CYP3A4 responsive elements.  In vitro translated wild-type or 
Trp223Ala/Tyr225Ala PXR (0.1, 0.5 or 1 μL) were combined with equal amounts of 
RXRα protein and incubated with NR3 (caTGGACTttccTGACCCca) or ER6 
(ataTGGACTcaaaggAGGTCAgtg) elements from CYP2B6 and CYP3A4, respectively. 
Oligonucleotides were labeled with [γ-32P]dATP, and mobility shift assays were 
performed as described in “Experimental Procedures”. 
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Figure 3.4C. Mutant PXR LBD can bind to RXRα LBD in vitro. 
Trp223Ala/Tyr225Ala double-mutant PXR LBD is competent to bind to the LBD of 
RXRα.  Wild-type or double-mutant PXR LBD’s were incubated with biotin-labeled 
RXRα LBD in the absence and presence of the PXR agonist SR12813 at 50 μM.  RXR 
was then immobilized on streptavidin beads, and the beads extensively washed.  Bound 
proteins were eluted and examined by SDS-PAGE, and the bands for the 36.2 kDa PXR 
LBD are shown. 
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Figure 3.5A. Mutant PXR does not interact with SRC-1 in mammalian two-hybrid 
assay. Mammalian two-hybrid examination of the interaction between full-length PXR 
and the nuclear receptor interaction domain (NRID) of the transcriptional coactivator 
SRC-1.  Wild-type and Trp223Ala/Tyr225Ala double-mutant PXR were examined alone 
and in the presence of the PXR agonist SR12813. 
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Figure 3.5B. Mutant PXR LBD does not interact with SRC-1 peptide pull-down 
assay. In vitro examination of the interaction between PXR LBDs and an SRC-1 peptide.  
Only wild-type PXR LBD interacted with a biotinylated SRC-1 peptide, while a 
Trp223Ala/Tyr225Ala double-mutant PXR LBD was not observed to bind to the same 
peptide. 
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Figure 3.6A. Superposition of PXR LBD homodimer interface on TrpZip4. 
Superposition of the PXR LBD homodimer interface on TrpZip4 (Cochran, A.G., et al. 
2001).  PXR residues 222-226 are shown in cyan.  Residues 41-56 of Trpzip4 are 
rendered in magenta. 
 
 
 
 
 
 
 
 114
  
 
 
Figure 3.6B. Comparison of PXR and CAR LBD structures. A side-by-side 
representation of the LBDs of PXR and CAR (Shan, L., et al. 2004; Suino, K., et al. 
2004; Xu, R.X., et al. 2004).  The extended β-sheet region of PXR is rendered in green.  
The β-sheet region of CAR is depicted in yellow.  Unlike PXR, CAR contains a capping 
α-helix (shown in magenta) that protects its edge β-strand from non-specific interactions.   
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Figure 3.6C. Model of the PXR/RXRα heterotetramer. A model for the PXR/RXRα 
heterotetramer complex of ligand binding domains. The PXR-RXRα heterotetramer was 
generated using the structure of PPARγ-RXRα complex as a template (Gampe, R.T., Jr., 
et al. 2000a).  The PXR LBD homodimer is shown in blue and yellow with the RXRα-
LBDs in green and magenta.  The PXR LBDs in this figure are viewed in the same 
orientation shown in Figure 1.2A. 
Chapter 4 
Biophysical Characterization of PXR LBD and Mutants 
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Abstract 
 
The nuclear pregnane X receptor (PXR) regulates expression of many genes 
essential in mammalian drug metabolism including cytochrome P450-3A4 (CYP3A4), 
which metabolizes more than 50% of all prescription drugs. PXR is a ligand-activated 
transcription factor that responds to a wide variety of structurally distinct compounds. 
Biophysical characterization of wild-type PXR LBD and two specific mutants that confer 
changes in basal transcriptional activity was carried out. The mutants are based on salt 
bridges on the surface of PXR’s LBD that appear to gate the entrance to the ligand 
binding pocket. Individual mutations of “charge-gate” residues to alanine significantly 
impact the basal transcriptional activity of PXR, and therefore could shed light on the 
regulation of PXR. These mutations could impact basal transcriptional activity of the 
receptor by introducing detailed structural changes that are reflected in gross alterations 
in protein stability and changes in the ability to recruit transcriptional coregulators. The 
thermal stabilities of wild-type and mutant forms of PXR LBD were determined using 
circular dichroism spectropolarimetry (CD).  
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Introduction 
 
The nuclear pregnane X receptor (PXR) regulates expression of many genes 
essential in mammalian drug metabolism including members from the 2B and 3A 
subfamilies of cytochrome P450s (CYP2B and CYP3A) and the xenobiotic efflux pump 
MDR1 (human multidrug resistance 1 protein) (Goodwin, B., et al. 2002) The 3A4 
isoform is the predominant CYP expressed in the human adult liver and small intestine; 
this isoform is known to metabolize greater than 50% of prescription drugs and is thought 
to be the key player in drug-drug interactions (Guengerich, F.P. 1999; Li, A.P., et al. 1995; 
Maurel, P. 1996; Michalets, E.L. 1998). PXR is a ligand-activated transcription factor that 
responds to a wide variety of structurally distinct compounds. Ligand-activated 
transcription by other nuclear receptors is mediated by coactivator and corepressor 
proteins (collectively called coregulators). The interactions of PXR with coactivators are 
relatively well-characterized, and a crystal structure of a fragment of SRC-1 (steroid 
receptor coactivator-1) bound to the PXR ligand binding domain (LBD) has been 
determined (Watkins, R.E., et al. 2003a). 
The PXR LBD structure is shown in Figure 1.2B; it contains ten alpha helices 
and a five-stranded beta sheet (in comparison to the typical nuclear receptor’s three-
stranded beta sheet). (Watkins, R.E., et al. 2001; Watkins, R.E., et al. 2003a; Watkins, 
R.E., et al. 2003b) The ligand-binding pocket is very large (1100-1500Å3) and 
predominantly hydrophobic with the eight polar residues evenly distributed throughout 
the twenty hydrophobic residues that line the pocket. (Watkins, R.E., et al. 2001) The 
coactivator fragment (yellow in Figure 1.2B) binds in a groove formed with residues 
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from αAF (activation function), α3, and α4; the coactivator binds adjacent to the AF2 
helix that is responsible for ligand-dependent transcriptional activation (labeled αAF in 
Figure 1.2B).  
In the crystal structures of the human PXR ligand binding domain (LBD) two salt 
bridges (R410-E321 and R413-D205) on the surface of PXR appear to gate the entrance 
to the ligand binding pocket (Figure 4.1). (Watkins, R.E., et al. 2001) Interestingly, 
individual mutations of these “charge-gate” residues to alanine significantly impact the 
basal transcriptional activity of PXR as determined by a luciferase reporter gene assay in 
CV-1 cells transfected with human PXR and the xenobiotic-responsive enhancer module 
from CYP3A4, then treated with SR12813 or rifampicin (Figure 4.2). (Watkins, R.E., et 
al. 2001) The largest effects were observed in the R410A mutant, which increased the 
basal activity of PXR, and the D205A mutant, which eliminated basal activity. (Watkins, 
R.E., et al. 2001) Addition of ligand was able to restore all activity for the D205A mutant; 
and, although R410A responded to ligand, the difference between R410A and wild type 
activity at the highest concentration of ligand was much smaller than the difference 
observed in the absence of ligand and at low concentrations. These mutations could 
impact basal transcriptional activity of the receptor by introducing detailed structural 
changes that are reflected in gross alterations in protein stability and changes in the 
ability to recruit transcriptional coactivators and corepressors. Thermal stability of wild-
type PXR LBD and the R410A and D205A mutant LBDs was determined using circular 
dichroism spectropolarimetry. Results of this study demonstrate that the changes due to 
charge gate mutations do confer an overall change in the thermal stability of the protein. 
To determine whether the mutations changed the structure of the PXR LBD, 
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crystallization trials were conducted; however, neither the R410A nor the D205A protein 
produced crystals. 
 
Materials and Methods 
 
Protein Expression and Purification   
Pure wild-type and mutant PXR LBDs were expressed and purified using 
modifications of the published protocols (Watkins, R.E., et al. 2001). Briefly, human PXR 
LBD (residues 130-434) was His-tagged and coexpressed with a fragment of SRC-1 in 
BL-21 Gold cells (Stratagene). Cells were lysed by sonication, and the clarified cell 
lysate was purified using ProBond nickel-chelating resin (Invitrogen). For CD studies, 
the fractions appearing pure based on SDS PAGE were combined and dialyzed into a low 
salt, phosphate buffer (20 mM sodium phosphate pH 7.8, 100 mM NaCl, 2.5 mM EDTA, 
10 mM β-mercaptoethanol, 5% glycerol) which is necessary to minimize noise in the 
spectrum and maintain a moderate absorbance level. After dialysis, the protein was 
concentrated to 0.5 mg/mL. Using this method, 3 mg of pure wild-type PXR, 10 mg of 
PXR R410A, and 5 mg of D205A were obtained per 8 L culture. For crystallization trials, 
the Ni-column fractions were analyzed using a Bradford assay only, and all fractions 
containing protein were loaded to an SP sepharose column as they eluted from the Ni-
column. Protein eluted from the SP column was diluted to prevent precipitation caused by 
high salt concentrations. The fractions containing PXR were concentrated to 7 mg/mL for 
crystallographic studies. Using the additional column decreases the yield of all forms of 
 121
PXR to approximately 1 mg per 8 L culture, but removes low concentration impurities 
(visible by SDS PAGE only with silver staining) that seem to impede crystallization. 
 
Thermal Denaturation. 
 Thermal stabilities of wild-type, D205A, and R410A PXR LBD in the presence 
and absence of ligands and a fragment of the coactivator SRC-1 were determined using 
circular dichroism spectropolarimetry (CD). Biophysical characterization of wild-type 
PXR and mutants of PXR was initiated by Paula-Davis Searles at University of North 
Carolina at Chapel Hill. The circular dichroism signal at 222 nm (indicative of alpha 
helix) was monitored as the temperature was changed by 1ºC/min from 4ºC to 85ºC. 
Samples were prepared and incubated on ice for at least 15 minutes after 10x ligand or 
10x SRC-1 was added. Data was collected on an AVIV circular dichroism spectrometer 
Model 62DS at the Macromolecular Interactions Facility at University of North Carolina 
at Chapel Hill. The 25 amino acid fragment of coactivator SRC-1 (676-
CPSSHSSLTERHKILHRLLQEGSPS-700, where the LxxLL motif is in bold) >98% 
pure was purchased from SynPep. Rifampicin was purchased from Sigma Aldrich, and 
SR12813 was a gift from GlaxoSmithKline.  
Once collected, the data was analyzed in Sigma Plot using a two-state fit for 
denaturation according to the reaction scheme 
N         D  
The equations combined for the regression have been previously described.(Allen, D.L., 
et al. 1998; Cohen, D.S., et al. 1994) (Equations 1 and 2.)  
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Aλ,T =
λN,T + KD,T(λD,T)
1 + KD,T  Equation 1. 
 
{                }KD,T = -exp RT ΔHm [1- (      )] - ΔCp [(Tm- T) + T ln(      )]
T
Tm
T
Tm
 Equation 2. 
Where Aλ,T is the polarization of the light at wavelength λ and temperature T (in Kelvin), 
λN,T is the polarization due to the native (N) baseline at temperature T, KD,T is the 
apparent equilibrium constant for denaturation at temperature T, λD,T is the absorbance 
due to the denatured (D) baseline at temperature T, ΔHm is the van’t Hoff enthalpy of 
denaturation, Tm is the temperature at which half of the protein molecules are denatured, 
ΔCp is the heat capacity of D minus N, and R is the gas constant. 
 
Results and Discussion 
 
The results obtained thus far for wild-type, D205A, and R410A PXR LBD in the 
presence and absence of ligands or coactivator fragment are presented in Table 4.1. 
Indeed, a correlation is evident between thermal stability and basal transcriptional 
activity; the mutant without basal activity shows a decreased thermal stability (from 43.1 
± 0.1°C for wild-type to 37.7 ± 0.4°C for D205A), while the mutant with increased basal 
activity shows an increased thermal stability (from 43.1±0.1°C for wild-type to 
46.5±0.8°C for R410A). In addition, both ligand and coactivator binding confer stability 
to all forms of PXR. Ligand induced a greater increase in D205A Tm than in wild-type Tm 
and less increase in R410A Tm than in wild-type Tm, while SRC-1 binding conferred 
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greater increases in Tm to both mutants than it did to wild-type. This pattern of stability 
change conferred by SRC-1 for R410A could contribute to its ability to act above the 
maximal level established by wild-type in the luciferase reporter gene assays. 
An unusual structural feature of the PXR LBD is the novel α2 helix present when 
coactivator peptide is observed bound (Figure 1.2B).(Watkins, R.E., et al. 2003a) This 
helix is not present in any other nuclear receptors or PXR LBD in the absence of 
coactivator peptide. The residue that shows that greatest change in position is Leu209, 
which is shifted significantly (7.7 Å) between the PXR LBD structure with SR12813 and 
the PXR LBD/SR12813/SRC-1 structure suggests that α2 is linked to coactivator 
binding. Figure 4.3 shows Asp205 and Leu 209 side chains rendered as sticks; Asp205 is 
on the same face of the helix, one turn away, as Leu209. The transcriptional activity data 
from the charge-gate mutants may suggest that the positioning of α2 is critical to 
transcriptional activation because loss of Asp205, which holds α2 in its position, 
abolishes basal activity. This would also explain why individual loss of Glu321 or 
Arg413 has less of an effect on activity; as Figure 4.1 shows, Glu321 is not involved in 
positioning α2 at all and loss of Arg413 could be mitigated by weak interactions between 
Asp205 and the remaining Arg410. Therefore, it is possible that mutating Asp205 to 
alanine favors a conformation that facilitates corepressor binding. Addition of agonist is 
able to fully restore transcriptional activity of D205A, suggesting the induced change is 
completely overcome by ligand contacts. The effect of the R410A mutation is more 
difficult to understand. Arg410 does make a water-mediated contact to the ligand 
(SR12813) in structures, but it is not clear that changing the residue to alanine could 
effect this interaction in a way to contribute to its high basal activity. Because the ligand 
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makes van der Waals contacts with the αAF-2 helix, the R410A activity could also be 
explained by causing a favorable change in the AF2 region for binding of coactivator. It is 
also possible that removing Arg410 allows a better interaction of Asp205 and Arg413, 
and thereby stabilizes α2. These questions cannot be answered until crystal structures for 
the mutants are determined. 
Crystallization trials were performed with the PXR R410A mutant using both 
sparse matrix and focused screens (using previously determined crystallization conditions 
from Syrxx screen and the literature (Watkins, R.E., et al. 2001; Watkins, R.E., et al. 
2003a; Watkins, R.E., et al. 2003b)). Unfortunately, many wells of the sparse matrix 
screens contained denatured precipitate. The focused screens produced denatured 
precipitate, phase separation, and birefringent spherulites. Some small crystal plates of 
R410A grew in the screens around Syrxx conditions (100 mM HEPES, PEG 6000, LiCl, 
pH 6.8-6.9 and 7.2-7.3). However, the crystal quality was poor and optimization was 
unsuccessful. To date, crystallization conditions for R410A and D205A remain elusive. 
Although additional data on E321A and R413A would augment this study, the 
results presented here demonstrate that the mutants that change basal transcriptional 
activity have reflective changes in protein stability in vitro. Because the position of the 
residues and their link to the αAF helix suggest that these changes in thermal stability 
reflect structural changes that could also alter the receptor’s ability to bind coregulator, 
the ability of different coactivators to potentiate transcription of wild-type and mutant 
PXRs should be compared.  In vivo effects of stability changes should be investigated by 
examining degradation and the effects of proteosomal inhibitors. The mutants examined 
in this proposal are worthy of investigation for gene therapy as they could significantly 
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alleviate severe cases drug-drug interactions by allowing medical practitioners to 
attenuate PXR’s response to specific xenobiotics. 
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Table 4.1. Melting temperatures of wild-type and mutant PXR LBD. Melting 
temperatures (in °C) of wild-type and mutant forms of the PXR LBD determined by CD. 
(Numbers in parenthesis indicate number of replicates, n.d. indicates values not yet 
determined.) 
 no ligand SR12813 rifampicin SRC-1 
SR12813 
+SRC-1 
rif 
+ SRC-1 
Basal 
Activity 
hPXR 
(wt) 
43.1 + 0.1 
(3) 
48.1 + 0.7 
(4) 
46.5 + 0.5 
(4) 
47.8 + 0.6 
(3) 
50.2 + 0.1 
(3) 
52.6 + 0.3 
(3) 
++ 
hPXR-
D205A 
37.7 + 0.4 
(3) 
46.6 + 0.3 
(6) 
45.8 + 0.2 
(8) 
44.7 + 0.1 
(7) 
48.8 + 0.2 
(5) 
47.9 + 0.1 
(8) 
None 
hPXR-
R410A 
46.5 + 0.7 
(4) 
48.9 + 0.1 
(3) 
47.0 + 1.6 
(4) 
52.0 + 2.1 
(5) 
55.1 
(1) 
53.6 + 5.0 
(4) 
++++ 
hPXR-
R413A 
n.d. n.d. n.d. n.d. n.d. n.d. + 
hPXR-
E321A 
n.d. n.d. n.d. n.d. n.d. n.d. + 
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Figure 4.1. Charge-gate residues of PXR ligand binding pocket. [Figure from R.E. 
Watkins et al. (2001) Science 292:2329-33. Reprinted with permission from AAAS.] 
Close-up view of the R410-E321 and R413-D205 salt bridges gating the ligand binding 
pocket of PXR LBD. (The ligand SR12813 is shown in three different orientations in the 
ligand binding pocket.) 
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Figure 4.2. Transcriptional activity of wild type and mutant PXR LBD. [From R.E. 
Watkins et al. (2001) Science 292:2329-33. Reprinted with permission from AAAS.] 
Results of the luciferase reporter gene assay for wild-type and mutant PXR, performed in 
CV-1 cells with increasing concentrations of ligand. 
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Figure 4.3. Location of leu209 in relation to charge-gate residues. Structure of human 
PXR LBD with SRC-1 peptide (purple) and SR12813 bound (not shown). Generated 
from 1NRL.(Watkins, R.E., et al. 2003a) The αAF is shown in blue. The arginines side 
chains that participate in the charge gate are shown in black, while the acidic residue side 
chains are shown in yellow. Leu209 (orange) moves the most when compared to the 
structure where activator is not bound and is Leu209 is on the same side of the helix as 
Asp205. 
Leu209
Asp205
Glu321 Arg410
Arg413
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